Newsroom

Error message

Notice: Undefined offset: 1 in eval() (line 24 of /var/www/sites/all/modules/views/plugins/views_plugin_argument_validate_php.inc(51) : eval()'d code).

Press releases

inVentiv Health Names Michael Bell Chairman and Chief Executive Officer

Bell to Drive Seamless Orchestration of inVentiv’s Clinical and Commercial Capabilities to Help Biopharmaceutical Companies Speed Innovation to Patients

BURLINGTON, Mass. – September 25, 2014 – inVentiv Health (“inVentiv”), a life science knowledge and services company for the new healthcare environment, today announced that the inVentiv Health Board of Directors appointed Michael Bell as Chairman and Chief Executive Officer (CEO), effective immediately. Paul Meister, formerly Chairman and CEO, will continue his role as a member of the Board of Directors.

Bell brings valuable experience gained over a distinguished three-decade management career at leading global services companies to the organization. Prior to his role as CEO, Bell held the position of Chief Operating Officer of inVentiv. In his new position, he will continue to identify operational efficiencies and strategic synergies across inVentiv to help solve biopharmaceutical clients’ most challenging problems.

“Mike’s an industry veteran who has managed sophisticated global service organizations through every stage of growth. That’s the ideal skill set to accelerate inVentiv’s continued success,” said Meister. “At inVentiv Mike has proven himself to be an extraordinary leader focused on operational excellence, strategic innovation, and cultivating talent at all levels of the organization. We know that both clients and employees will benefit tremendously from his business and healthcare acumen.”

Previously, Bell served as Senior Executive Vice President of John Hancock Financial Services, where he nearly doubled the growth rate of the businesses he managed. Prior to this role, he was a co-founder of the Monitor Group where he worked with companies across the healthcare delivery continuum, significantly expanding the organization’s global footprint. Bell also served as a founder and managing partner of Monitor Clipper Partners, a private equity firm specializing in professional, procurement, and pharmaceutical marketing services.

inVentiv has vast clinical development and commercialization capabilities. The company’s clinical capabilities are comprised of a leading CRO known for its broad therapeutic expertise and state-of-the-art systems that are scaled to need. Its commercial capabilities support every phase and function in commercialization – from consulting to sales teams to adherence programs – offering a comprehensive outsourcing model that provides clients with a critical competitive edge.

"I’m looking forward to leading a global organization of 12,000 talented healthcare professionals who are reinventing the way biopharmaceutical clients develop and commercialize products,” said Bell. “Partnering with companies at every step along the way, from first molecule to full marketing, we’re pioneering insightful services and outsourcing models to help clients navigate an increasingly complex marketplace.

“We've identified a noble mission – to help clients accelerate the delivery of healthcare innovation to the patients who need it most. I couldn't imagine a more exciting and meaningful venture.”

Bell serves as Chairman Emeritus of Brigham and Women's Hospital in Boston, MA, and previously served as a trustee and the Chair of Brigham and Women's Faulkner Hospital. Bell received his B.S. from The Wharton School at the University of Pennsylvania and attended Harvard Business School for his M.B.A.

About inVentiv Health
inVentiv Health, Inc. is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our clients’ development and commercialization goals. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health’s clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. For more information, visit www.inVentivHealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays, cancellations and termination; our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of our acquisition of Catalina Health Resource, LLC and any future acquisitions; the impact of any change in our current credit ratings or the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and our clients, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; the impact of impairment of goodwill and intangible assets and the factors leading to such impairments; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Health Announces The Inclusion Of Four Company Executives Among PharmaVOICE 100 Most Inspiring Leaders

Bob Chandler, Paul Harrington, Susan Perlbachs and Sydney Rubin Honored by Colleagues and Clients in the Life Sciences Industry

BURLINGTON, Mass. – August 4, 2014 – inVentiv Health, a life science knowledge and services company, announced today that four of its senior executives have been named to the prestigious PharmaVOICE 100 list of the most inspiring leaders in the life sciences industry. The inVentiv executives were selected among hundreds of nominees for outstanding leadership and innovation.

The four winners include Bob Chandler of Chandler Chicco Companies; Paul Harrington of Palio+Ignite; Susan Perlbachs of GSW New York, and; Sydney Rubin of inVentiv Health. The awards are granted based on nominations submitted by colleagues and clients.

“We congratulate the honorees who embody the kind of deep healthcare expertise and commitment to innovation that has made inVentiv Health an industry leader,” said CEO Paul Meister. “They are an inspiration to their colleagues and a credit to our profession.”

inVentiv’s winners lead and mentor teams across a global company of 12,000 employees. Their work spans decades and includes several healthcare disciplines as described in the current edition of PharmaVOICE magazine:

  • Bob Chandler, Chandler Chicco Companies: The inclusion of Bob Chandler on this year’s list pays tribute to his life-long mission to improve communications among patients, physicians, insurers and the providers of healthcare products and services. Bob built a new breed of PR agency – a flat agency with an empowered workforce focused on healthcare – which today includes more than 400 staff in New York, Washington, D.C., Philadelphia, Los Angeles, London, Paris, Frankfurt and Shanghai. Always ahead of the curve, he envisioned the possibilities of the “activated patient” long before the Internet or talk of patient-centric medicine. His innovative campaigns armed patients with knowledge about their treatment options, and improved communications between physicians and patients.
  • Paul Harrington, Palio+Ignite: Paul Harrington is transforming the healthcare industry by elevating creativity and building brands with simple, powerful stories. For more than 25 years, Paul has been producing award-winning creative in both consumer and healthcare accounts, across a wide range of media. At Palio+Ignite, an advertising agency that fuses art and science with technology and imagination, Paul has worked tirelessly to launch landmark campaigns and bring brands to life. He is the driving force behind Palio+Ignite’s global campaign for the world’s first once-weekly treatment for type 2 diabetes, Bydureon. Paul leads the biocoastal Bydureon team, who was named the Brand Team of the Year by Med Ad News.
  • Susan Perlbachs, GSW: As the executive director at the New York office of GSW, a leading healthcare advertising agency, Susan creates an environment where ideas are king and safe thinking gets squashed fast. Imbued with a competitive fire and relentless pursuit of the most powerful and perfect story, Susan strives constantly to ensure that the brands she manages succeed in the marketplace. She brings an array of experience to the role spanning 18 years, and she has enjoyed enormous success over this period with DTP and DTC audiences in areas that range from oncology brands to over-the-counter products.
  • Sydney Rubin, inVentiv Health: Sydney’s focus has been to position inVentiv Health as a global operating company with a reputation for excellence. During her time with inVentiv Health, she designed and developed the first social enterprise-wide intranet to encourage collaboration while also embarking on an external communications campaign that included message development for each of inVentiv’s nearly two dozen businesses. Sydney’s true passion lies in helping develop the next generation of professional communicators, delivering some of inVentiv’s most popular professional development workshops in which she shares both professional skills and her love of language.
    • “These trailblazers use their experience and innovative thinking to help our clients navigate an increasingly complex operating, regulatory and reimbursement environment,” said Meister. “We are proud to call them our colleagues.”

      About inVentiv Health
      inVentiv Health, Inc. is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our clients’ development and commercialization goals. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health’s clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. For more information, visit www.inVentivHealth.com.

inVentiv Health Initiates Refinancing Transactions To Fund Continued Growth

BURLINGTON, Mass. – July 15, 2014 – inVentiv Health, a life science knowledge and services company, announced today that it has initiated a series of capital market transactions to fund continued growth.

The transactions will extend debt maturities and substantially reduce cash interest expense. Funds affiliated with Thomas H. Lee Partners, L.P. and other existing investors will invest an additional $50 million of capital in inVentiv in connection with these transactions, consistent with their support of the company’s strategy and growth prospects.

“These transactions reflect the strength of our service offering and business outlook, and allow inVentiv Health to invest in incremental growth opportunities and enhance our capabilities as a leading healthcare services provider to the global biopharmaceutical industry,” said inVentiv Health CEO Paul Meister.

The transactions are expected to close within 30 days. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the financing described in this release, nor does it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. The financing offered will not be or has not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About inVentiv Health
inVentiv Health, Inc. is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our clients’ development and commercialization goals. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health’s clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. For more information, visit www.inVentivHealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays, cancellations and termination; our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of our acquisition of Catalina Health Resource, LLC and any future acquisitions; the impact of any change in our current credit ratings or the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and our clients, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; the impact of impairment of goodwill and intangible assets and the factors leading to such impairments; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

ACRES and inVentiv Health Partner to Promote Operational Excellence and Shared, Global Clinical Research Platform

inVentiv’s Otis Johnson Joins Site Optics and Quality Informatics (SOQI) Steering Committee for Development of Industry Wide Site-Based Performance Metrics and Informatics Standards

BURLINGTON, Mass. – July 10, 2014 – inVentiv Clinical Trial Recruitment Solutions (iCTRS), created to accelerate trials, and the Alliance for Clinical Research Excellence and Safety (ACRES), an Alliance-driven non-profit organization operating in the public interest and dedicated to enhancing quality, safety, integrity and operational effectiveness in drug development and health research, are partnering to fast-track the development of a global system to support responsible conduct of clinical trials according to the highest standards of safety, quality and efficiency.

Numerous challenges limit the pace of progress for global clinical research. According to ACRES, the industry squanders $20 billion annually due to inefficiencies inherent to the current process of bringing a new drug to market. Uniform global standards for research sites and independent third-party accreditation are lacking, as are interconnectivity and interoperability. Standards support the objective identification and assessment of sites, delivering improved system management and long-term sustainability.

The partnership between ACRES and inVentiv focuses on developing and adopting global standards and performance metrics as the basis for clinical research best practices and guidelines, to encourage operational excellence. iCTRS brings expertise in global, data-driven decision support systems, advanced informatics technologies and a patient-centric approach for trial acceleration.

To further augment the partnership, Otis Johnson, Vice President of Clinical Research Services at iCTRS, will join the Steering Committee of ACRES’ Site Optics and Quality Informatics Initiative (SOQI), focused on the development of a global information platform for effective trial management. The open access infrastructure will offer a collaborative network housing a massive data repository for worldwide data exchange. Johnson, a recognized thought leader in the industry, brings innovative solutions and thorough understanding of responsible ‘big data’ management and analytics, critical to the new system.

“iCTRS brings the clinical experience and global capabilities needed to help facilitate a comprehensive information management strategy necessary for the development of a global system,” says Dr. Greg Koski, President and CEO of ACRES. “We look forward to Mr. Johnson joining the SOQI initiative, and leveraging his extensive clinical research, development and operations expertise.”

“We’re excited to join the ACRES Global Network as they set the standard for clinical excellence measures that will transform the industry,” said Otis Johnson. “Together we’ll promote new standards worldwide by creating awareness, building strategic industry alliances and raising the bar for clinical research sites.”

As part of inVentiv Health, iCTRS’ innovative capabilities to recruit and retain patients, draws upon expertise from over a dozen inVentiv Health business units that focus on the development and commercialization of drugs and other medical products for the life sciences industry. inVentiv Health has directly supported the development and/or commercialization of 60% of all drugs approved by the FDA in the last 5 years.

“inVentiv Health, with their extensive network of biopharmaceutical service companies worldwide, shares our vision of raising the standard of excellence,” Koski added.

About ACRES
ACRES, a neutral, non-industry organization, is bringing together diverse stakeholders in building a global system for clinical research that seeks to accelerate the development of safe, effective therapeutics and medical devices to improve the quality of life and productivity of all people world-wide. For more information, visit www.acresglobal.net

About inVentiv Health
inVentiv Health, Inc. is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our client’s development and commercialization goals. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health’s clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. For more information, visit www.inVentivHealth.com

inVentiv Health and Aprecia Pharmaceuticals Form Innovative Partnership To Commercialize Aprecia’s Unique Technology Platform

Aprecia is the first and only company offering the proprietary ZipDose® product platform that leverages three-dimensional printing (3DP) to create fast-melt pharmaceuticals

inVentiv Health, the industry’s only full commercialization outsourcing organization, provides Aprecia the expertise and resources to launch its company and initial pharmaceutical products

BURLINGTON, MA and LANGHORNE, PA – June 4, 2014 – inVentiv Health (“inVentiv”), a life science knowledge and services company, and Aprecia Pharmaceuticals (“Aprecia”), a specialty pharmaceutical company, announced today an exclusive sales and marketing alliance.

This partnership will launch the Aprecia brand, as well as provide comprehensive commercialization of Aprecia’s pioneering technology platform and initial pharmaceutical products.

Aprecia is the first and only pharmaceutical company offering the proprietary ZipDose® product platform using three-dimensional printing (3DP) technology to create fast-melt products. These products promise to change how patients experience taking their medicine by making drugs easier to administer and swallow. Aprecia has completed clinical work and expects to file its first New Drug Application with the Food and Drug Administration (FDA) in the second half of 2014.

inVentiv Health has directly supported the development and/or commercialization of 60 percent of all drugs approved by the FDA in the last 5 years. By partnering with inVentiv, Aprecia gains access to the industry’s only full commercialization outsourcing organization.

Under the terms of the agreement, inVentiv will partner with Aprecia as its exclusive provider of comprehensive commercialization services and will share in the success of the commercialization efforts. inVentiv will invest time and materials to launch Aprecia and to commercialize its products in exchange for a negotiated royalty from future sales. inVentiv’s services include: sales teams and sales training, strategic and tactical market access services, non-personal promotion, advertising, public relations, adherence services, and full management of the commercialization teams.

“Getting medicine into the human body reliably and accurately is both a challenge and an enormous opportunity,” said Don Wetherhold, Chief Executive Officer of Aprecia. “To realize the potential of our technology and move quickly into market, we sought a partner that could execute every phase and function in commercialization -- and inVentiv was the obvious choice.”

Wetherhold added that with access to inVentiv’s vast commercial services, “Aprecia anticipates achieving rapid market penetration while retaining control of our proprietary products.”

Michael Griffith, Executive Vice President of inVentiv Health, said,“inVentiv Health offers innovative companies a unique outsourcing model for comprehensive commercialization.”

“We are pleased to have entered into this agreement with Aprecia and are looking forward to introducing their innovative technology platform and their much-needed products. Because of our unmatched expertise of pharmaceutical launches, clients know they can count on inVentiv Health to transform their assets into commercial success,” Griffith said.

About Aprecia
Aprecia is a unique specialty pharmaceutical company built upon an innovative and proprietary three dimensional printing (3DP) technology platform. The company has an exclusive worldwide license for 3DP originally developed at Massachusetts Institute of Technology for use in pharmaceutical applications. Aprecia’s 3DP platform can give rise to multiple product enhancing dosage forms to be used in a variety of therapeutic categories. The company expects that its initial products will be based on its proprietary, orally-dispersing ZipDose® technology. Aprecia’s ZipDose® products will focus on opportunities where there is an unmet need for medicines that are easier to take — children, elderly, and special patient groups. Aprecia expects to file its first New Drug Application with the FDA the 2nd half of 2014. The company is privately owned, with Prasco Laboratories, and the E. Thomas Arington Family holding controlling interest. For more information visit http://www.aprecia.com.

About inVentiv Health
inVentiv Health, Inc. is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our client's development and commercialization goals. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health's clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. For more information, visit http://www.inVentivHealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of our acquisition of Catalina Health Resource, LLC and any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Clinical Trial Recruitment Solutions To Discuss Using The Digital Ecosystem To Speed Patient Recruitment In China

iCTRS General Manager to Speak to 1,400 at 6TH Annual DIA China Meeting

PRINCETON, NJ – May 14, 2014 – inVentiv Clinical Trial Recruitment Solutions (iCTRS), created to accelerate trials, will speak to an expected audience of 1,400 people Wednesday on leveraging the digital ecosystem to speed clinical trial recruitment in China.

Ramita Tandon, senior vice president and General Manager of iCTRS, will speak at the 6th Annual DIA China Meeting on "Enhancing Clinical Trial Quality with Internet Technologies: Fueling Clinical Trial Recruitment through an Analysis of the Digital Ecosystem."

iCTRS was specifically created to integrate an innovative set of global capabilities to accelerate trials in a predictable and cost-efficient way. Tandon’s talk will be based on inVentiv’s use of digital, mobile, and social technologies to speed patient recruitment and how these technologies can best be used in China.

"Around the world, pharmaceutical companies are missing out on some of the best available digital tools to reach potential patients—and China is no exception," Tandon says. "Digital patient outreach campaigns geared to the culture and interests of individual patients can supplement traditional recruitment methods to increase patient awareness and support more enduring engagement."

Recruiting patients into clinical trials in China continues to be done primarily through physician referrals. As in other parts of the world, however, competition for patients in China is increasing and most patients are recruited through only a few treatment centers.

According to ChinaBio, difficulty in recruiting patients now accounts for 56% of trial delays in China, which contradicts the expectations of sponsors who believe China offers easy access to treatment naïve populations.

"Although recruiting challenges still cause fewer trial delays in China than in many developed markets, the problem of recruitment is growing," explains Tandon. "The most sophisticated companies understand the need for and are using cost effective and innovative methods for recruitment that go beyond reliance on investigators. Chinese patients are very reachable electronically."

According to the China Internet Network Information Center, 590 million people were using the Internet in China in mid-2013, making this the largest national population online anywhere in the world. The 2013 figure is an increase of nearly 10 percent over the prior year. Fifty-five percent of Chinese use the Internet, with 58 percent of users online daily, according to the Pew Research Global Attitudes Project. Meanwhile, cell phones are ubiquitous with 95 percent of Chinese owning cell phones and 37 percent owning smartphones, Pew reports.

“Our approach goes well beyond the traditional to focus on the patient, whether in Boston or Beijing,” Tandon says. “We analyze what drives people – or more importantly - what prevents -them from participating, And we know what keeps them in trials. The digital ecosystem is then leveraged to carry our messages.”

iCTRS has built novel capabilities to recruit and retain patients, tapping expertise across 23 businesses that have been working in drug development, commercialization and patient and physician engagement for decades. inVentiv Health is the only company in the world that can both develop and fully commercialize products for the life sciences industry – and has done more of it than anyone else in the industry.

In China, inVentiv Health’s office includes experts from iCTRS, inVentiv Health Communications and a range of other commercialization services.

About inVentiv Health
inVentiv Health, Inc. is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our client’s development and commercialization goals. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health’s clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. For more information, visit www.inVentivHealth.com

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of our acquisition of Catalina Health Resource, LLC and any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

Healthcare Businesswomen's Association Recognizes Five "Rising Stars" Working Across inVentiv Health

BURLINGTON, Mass. (May 1, 2014) – inVentiv Health, a life science knowledge and services company, announced today that five talented women executives have been selected as 2014 “Rising Stars” by the Healthcare Businesswomen’s Association (HBA). The honorees were recognized at the 25th annual HBA Woman of the Year award luncheon, held today in New York City, New York.

Each year, the HBA recognizes women from across the nation in the healthcare industry who exhibit visionary leadership skills, are solely dedicated to the healthcare industry, and contribute significantly to their organizations. To qualify as Rising Stars, honorees must also promote growth opportunities for others and serve as role models within their respective companies. All the inVentiv Health honorees are exemplary Rising Stars.

To celebrate the 25th anniversary of the awards, HBA created a first-ever “Luminary” category, acknowledging 25 previous Rising Stars who have continued to make a significant impact on the healthcare industry. Luminary award winners also must have experienced rapid career advancement since receiving their initial award.

Chandler Chicco Companies President, Lisa Stockman, was honored as one of the 25 HBA Luminaries. Stockman was named an HBA Rising Star in 2005. This year’s Rising Stars at inVentiv Health include Meg Alexander of Chandler Chicco Companies, Jemma Contreras of Campbell Alliance, Jeannine Doumar of GSW, and Julie Priddle of Palio+Ignite.

“These Rising Stars represent some of the most remarkable talent in healthcare. Each of these women is a respected expert in helping clients develop and commercialize drugs that improve patient outcomes worldwide,” said Mike Griffith, Executive Vice President. “On behalf of inVentiv Health, I want to congratulate each of these distinguished women on this well-deserved honor.”

The combined experience of inVentiv’s five honorees spans several decades and a variety of healthcare-specific disciplines, including consulting, advertising and public relations:

  • Lisa Stockman, President of Chandler Chicco Companies, has more than 20 years of communications leadership expertise, spearheading the development of innovative communications programs that create and nurture strategic stakeholder relationships.
  • Meg Alexander, Issues and Reputation Lead at Chandler Chicco Companies, successfully navigates Fortune 500 companies through some of the most challenging communications issues facing their industries.
  • Jemma Contreras, Director of Campbell Alliance’s Medical Center of Excellence, brings exceptional preclinical research experience in behavioral neuroscience to her client engagements.
  • Jeannine Doumar, Vice President/Associate Creative Director at GSW, has more than a decade of pharmaceutical advertising experience that spans a variety of therapeutic categories, from allergies to virology - and everything in between.
  • Julie Priddle, Vice President of Business Development at Palio+Ignite, has proven capabilities in creating and executing marketing and communications plans that drive brand leadership.

“Together, these five honorees are helping inVentiv Health redefine services for the biopharmaceutical industry,” Griffith said. “We are proud of their achievement.”

About inVentiv Health
inVentiv Health, Inc. is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our client’s development and commercialization goals. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health’s clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. For more information, visit http://www.inVentivHealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of our acquisition of Catalina Health Resource, LLC and any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

Kim Johnson Named President of Palio+Ignite

Johnson to Lead Creative Agency Helping Pharmaceutical Companies Accelerate Brand Performance

NEW YORK – April 29, 2014 – Palio+Ignite, an inVentiv Health communications agency known for creating compelling healthcare brands, announced today the appointment of Kim Johnson as President.

Johnson will chart the next phase of Palio+Ignite’s evolution, expanding the services it provides in medical, consumer, and managed markets communications, supported by innovative technologies. She’ll lead the agency’s three offices in New York City, New York, Saratoga Springs, New York, and Irvine, California.

For nearly two decades, Johnson has worked with some of the world’s biggest and most well-respected pharmaceutical companies, including Novartis, Pfizer, and Merck. She has deep professional, consumer, and digital marketing expertise, and a proven record of consistent double-digit business growth.

“Kim’s results-driven approach to marketing and her vast experience make her ideally suited to lead Palio+Ignite,” said Michael Griffith, Executive Vice President of inVentiv Health. “Her knowledge across the product lifecycle and commitment to innovative technology will optimize commercial success for our clients’ pharmaceutical brands.”

Prior to joining Palio+Ignite, Johnson was a partner at The CementBloc, where she oversaw numerous agency operations and was a driving force in transforming the organization from a traditional advertising agency to a full-service, integrated communications agency. She was responsible for significant new business growth and established the agency’s consumer and digital practices. Among her clients were Vertex, GlaxoSmithKline, and Johnson & Johnson.

Before The CementBloc, Johnson was at Pfizer, where she led the strategic direction, alignment, and prioritization of patient marketing for U.S. Celebrex. She also has held senior positions at businesses within Omnicom and Y&R.

“Palio+Ignite has tremendous equity in the marketplace,” Johnson said. “With a deep bench of medical strategists, innovative REMS and managed markets expertise, as well as proven technology capabilities, the agency is a creative healthcare powerhouse.”

Guy Mastrion, chief global creative officer and Palio+Ignite founder, said that Johnson is known for building talented, winning teams and for winning leading clients. “It’s an exciting time at Palio+Ignite, and we’re thrilled to have her on board.

“Kim shares our vision of owning the ‘moment,’ which means reaching patients and physicians at the moment when it matters most,” he said.

As part of inVentiv Health, Palio+Ignite has access to comprehensive commercialization services that are unmatched in the industry. Services such as patient outcomes and selling solutions offer clients a significant competitive advantage.

Johnson will be based in Palio+Ignite’s New York City office. She has a B.S. in marketing from Babson College and holds an adjunct professorship at New York University.

About Palio+Ignite
Palio+Ignite is a full-service agency that enables healthcare and pharmaceutical companies to reach and engage audiences through the power of communications. The agency is a creative force within the marketplace and brings differentiating strengths to the table: medical strategy, REMS, managed markets, market research, social marketing, health gaming and animation, brand strategy, insight and analytics, global outreach, digital communications and interactive development, mobile health, and emerging technologies. Together, we have the ability to provide clients with a heightened level of synergy and engagement through ideas and innovation. Palio+Ignite is part of inVentiv Health Communications (iHC), the inVentiv Health Division dedicated to delivering exceptional, global, multichannel communications to organizations focused on health and wellness. For more information visit palioignite.com

About inVentiv Health
inVentiv Health, Inc. is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our client’s development and commercialization goals. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health’s clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. For more information, visit www.inVentivHealth.com

inVentiv Health Clinical Engaged By IntelliCell BioSciences, A Regenerative Medicine Company, As Clinical Research Organization for Osteoarthritis IND

Dr. James Andrews, Respected Orthopedic Surgeon and Founding Member of American Sports Medicine Institute, To Serve as Principal Investigator

BURLINGTON, Mass. – April 15, 2014 – inVentiv Health Clinical, a leading global supplier of drug development services, announced today that it has been selected for an osteoarthritis Investigational New Drug Application (IND) by the innovative regenerative medicine biotechnology company IntelliCell BioSciences, Inc., (OTCQB:SVFC). IntelliCell will be studying the use of adult autologous vascular cells from blood vessels in adipose tissue to treat osteoarthritis of the knee.

The principal investigator is Dr. James Andrews, an orthopedic surgeon known internationally for his scientific and clinical research into knee, shoulder and elbow injuries. Dr. Andrews is a founding member of the American Sports Medicine Institute, author of numerous scientific articles and books and founding partner and medical director at the Andrews Institute in Gulf Breeze, Florida.

inVentiv Clinical will work with Dr. Andrews to develop investigational clinical study protocols and will serve as the Clinical Research Organization (CRO) on trials conducted at the Pensacola Center of the Andrews Institute.

IntelliCell’s technology for isolating stromal vascular fraction cells from the vasculature of adipose tissue has been used to treat more than 60 knees. IntelliCell’s Chief Executive Officer, Dr. Steven Victor, said this is what we believe will be the first of several clinical trials for the biotech company studying the use of its technology in treating a variety of diseases and conditions.

“inVentiv Clinical has extensive therapeutic experience in general pain and osteoarthritis programs and a focus on partnering with innovative bioscience companies,” said Raymond Hill, President of inVentiv Health Clinical. “We are looking forward to our work with Dr. Andrews and contributing to advances in the treatment of osteoarthritis in knees.”

inVentiv Health Clinical offers clients a full range of clinical research services supported by a global infrastructure, therapeutic expertise, and unmatched commitment to quality. For pharmaceutical, biotechnology, generic drug, and medical device companies, inVentiv conducts Phase I-III clinical trials, Phase IV late stage post-approval programs, as well as offering staffing, bioanalytical and regulatory services.

IntelliCell’s IND study will focus on proving the company’s patented technology of Ultrasonic Cavitation as a method of producing stromal vascular fraction cells as a new approach and improvement on current treatment which in the worst cases can involve surgery.

About 75% of people over 70 years of age show changes consistent with osteoarthritis and symptoms such as pain, joint stiffness and joint deformities. Osteoarthritis affects more than 25 million people in the United States alone.

Regenerative medicine is the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function by replacing damaged tissue and/or by stimulating the body's own repair mechanisms to heal previously irreparable tissues or organs.

IntelliCell is planning an in-human clinical trial in late 2014 to study if the IntelliCell vascular fraction cells may demonstrate measurable benefits for patients suffering from this debilitating condition.

About inVentiv Health
inVentiv Health, Inc. is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our client’s development and commercialization goals. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health’s clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. For more information, visit www.inVentivHealth.com

About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.

Next Generation Feasibility Webinar to Highlight Innovations That Improve Clinical Trial Feasibility and Reduce Trial TImelines

Webinar to Explore Cutting-Edge Use of Data Analytics that Challenges Traditional Approach to Feasibility Studies and Significantly Increases Predictability

BURLINGTON, Mass. (April 1, 2014) – inVentiv Clinical Trial Recruitment Solutions (iCTRS), created to accelerate trials efficiently and predictably, will discuss the latest innovations in trial feasibility during a webinar next week hosted by Clinical Informatics News.

Otis Johnson, executive director of feasibility and clinical informatics at iCTRS, will discuss approaches to leveraging data and analytics, as well as internal and external expertise to gather protocol and investigator intelligence prior to engaging sites. Leveraging innovation in the form of advanced technologies streamlines site selection and reduces the timelines associated with site feasibility to get a trial off on the right foot.

“The goal is to identify, qualify and enroll the highest performing investigators more quickly and effectively than ever before,” Johnson said. “But the ultimate goal is getting drugs into development and then into the marketplace faster for optimized revenue and for patients who need better treatment.”

The webinar at 1 p.m. EDT on April 8th is designed to teach attendees innovative approaches for feasibility analysis, better integration of data sources for more informed decisions and how to increase predictability in study enrollment timeframes through efficient site selection.

Johnson said that for many years, biopharmaceutical companies have made false assumptions on how long it takes to enroll a trial, how many sites are needed, in which countries they are needed and how many patients to enroll per site. The biggest mistake, he said, was counting on investigators themselves to produce all the required patients from their own practices.

According to Gartner, missing enrollment timelines cost clinical trial sponsors $37,000 a day in unexpected operational costs and much more in opportunity costs. To help address the problem, iCTRS has amassed a proprietary combination of global data on patients, investigators, sites and trials, as well as a novel set of analytical tools to gain insights from the data.

How this is done and to what effect will be the basis for much of Johnson’s presentation.

For more information on how to register for the Next Generation Feasibility Analysis webinar, visit: http://www.clinicalinformaticsnews.com/ecliniqua_webinar.aspx?id=135550.

About inVentiv Health
inVentiv Health, Inc. is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our client’s development and commercialization goals. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health’s clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide.For more information, visit http://www.inVentivHealth.com.

About Clinical Informatics News
Clinical Informatics News reports on innovative technologies from clinical trials to medical informatics. Technology continues to permeate all aspects of clinical trials and the patient experience, and the tools to support these efforts are maturing rapidly. ClinicalInformaticsNews.com and the Clinical Informatics News email newsletter provide authoritative news, views, and insights on the vast landscape of innovation between clinical trial management and delivery of care.

inVentiv Health's Campbell Alliance Launches Consulting Services in Japan for Clients Seeking Commercial Expertise and Support in Asia

Pawel Komender Appointed Regional General Manager to Lead the New Tokyo Office

BURLINGTON, Mass. and TOKYO, JAPAN (March 27, 2014) –Campbell Alliance, an inVentiv Health company and industry leader in biopharmaceutical consulting, today announced the launch of its consulting business in Japan and the opening of its Tokyo office. Campbell’s presence in Tokyo complements a dozen other locations in North America and Europe where inVentiv has on-the-ground consulting services.

The opening of the consulting office allows inVentiv to act as a strategic partner for any biopharmaceutical company conducting business in Asia. The Japanese office will offer all the services and expertise clients count on from inVentiv, including:

• Market Assessment and Opportunity Identification
• Pricing and Market Access
• Market Entry and Go-to-Market Strategy
• Product Launch
• Commercial Excellence and
• In- and Out-Licensing.

The Campbell Alliance office in Asia will operate as inVentiv Health Consulting.

“inVentiv Health Consulting will provide in–market capabilities and presence for U.S.-based companies looking to better understand the Japanese market,” said Darius Naigamwalla, President of Campbell Alliance “For Japanese clients wanting Japan-based support, we will provide local presence and accessibility. The office also will round out our industry-leading global Pricing and Market Access Capabilities, as well as offer seamless delivery of solutions to support all aspects of product development and commercialization. Our focus is on helping clients solve intricate problems, optimize emerging opportunities and succeed in an evolving marketplace."

In leading the new office, Pawel Komender will leverage nearly 20 years of professional experience in Japan and a track record of assignments in the Asia Pacific region. Prior to joining Campbell Alliance, Mr. Komender worked with Accenture Japan and Simon-Kucher & Partners. He is fluent in Japanese, English, German, and Polish.

“Pawel’s background in strategic consulting and his deep functional knowledge, as well as his experience working in the Japanese market, make him the ideal person to lead our consulting business and our anticipated growth in Japan,” Naigamwalla said.

For further information about inVentiv Health Consulting in Japan, please visit the Campbell Alliance website at http://www.campbellalliance.com/Japan/.

About Campbell Alliance
Campbell Alliance is the Consulting business segment of inVentiv Health and an industry leader in biopharmaceutical consulting. The firm's clients include all of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into three Centers of Excellence—Commercial, Medical, and Corporate Development—each of which offers a range of services to a critical area of the pharmaceutical and biotechnology industries. Each of our Centers of Excellence is a dedicated consulting team whose members are highly specialized and offer deep expertise in their chosen areas. From its 13 office locations, the firm serves clients throughout North America, Europe, and Asia. For more information on Campbell Alliance, please visit www.campbellalliance.com.

About inVentiv Health
inVentiv Health, Inc., is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our client’s development and commercialization goals. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health’s clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. For more information, visit http://www.inVentivHealth.com.

Mytrus Announces Innovation Advisory Board Made Up of Powerhouse Clinical Trial and Patient-Focused Experts

New Board Will Advise Mytrus On Developing Innovative New Products Essential For Improving Research and the Patient Experience in Clinical Trials

BURLINGTON, Mass. (March 18, 2014) – inVentiv Health, a life science knowledge and services company for the new healthcare environment, announced today the creation of a new Innovation Advisory Board comprised of leading industry experts who will help shape the future of clinical products and services offered by Mytrus, a pioneer in electronic informed consent and leader in e-clinical technologies.

inVentiv Health holds an equity stake in the California-based company that is changing the game in how patients are enrolled in clinical trials to dramatically improve the process, increase retention and speed clinical trials.

“The members of our new Innovation Board have held key positions in the pharmaceutical industry throughout their careers and have a long tradition of innovating improvements in clinical research,” said Mytrus CEO Anthony Costello, who also will serve on Innovation Advisory Board. “We are grateful for their willingness to work with us and we share a common commitment to improving the clinical trial experience for patients.”

Costello noted that research shows how better informed and more engaged patients lead to better research data and faster drug development timelines. “This group of experts have long recognized the importance of patient centricity in research and their input into our line of clinical trials technologies will be invaluable in helping us break new ground in trial improvement,” he said.

The six Innovation Advisory Board members include:

Steven Cummings, MD is co-founder of Mytrus and a leading expert in the design and implementation of clinical research studies. Dr. Cummings, the Chief Scientific Officer at Mytrus, also serves as Director of the San Francisco Coordinating Center, Emeritus Professor of Medicine, Epidemiology and Biostatistics at UCSF and Senior Scientist at CPMC Research Institute and Innovator-in-Residence at Roche-Genentech.

David G. Forster, JD, MA, CIP, Chief Compliance Officer, WIRB-Copernicus Group joined the Western Institutional Review Board in 1996 and currently serves as Chief Compliance Officer as well as a co-chair on a subcommittee of the Health and Human Services Secretary’s Advisory Committee on Human Research Protections.

Clay Johnston, MD, PhD is Dean of Medicine at the new University of Texas Dell Medical School in Austin. Dr. Johnston recently served as Director of the Clinical Translational Sciences Institute at the University of California, San Francisco, and is a leading expert in clinical trial methods.

Garry Neil, MD is Global Head of Research and Development at Medgenics and a leader in clinical trials innovation. At Johnson & Johnson, he served as Corporate Vice President of Science & Technology and Group President of Pharmaceutical Research and Development. Dr. Neil also is a Founder/Director and served as CEO of TransCelerate Biopharma, Inc., a respected, cross-industry initiative to improve the effectiveness and efficiency of industrial biopharmaceutical R&D.

Dr. John Orloff, MD is Global Head of Clinical Development at Merck Serono. Dr. Orloff recently served as Chief Medical Officer and Senior Vice President, Global Development for Novartis Pharma AG where he led the “Trials of the Future” initiative to bring innovation to the drug development process. He also served as Head of U.S. Medical and Drug Regulatory Affairs for North America.

Jane Perlmutter, PhD, MBA is a psychologist and leading patient advocate for clinical trial participants. Dr. Perlumutter also serves on the Clinical Trials Transformation Initiative on Informed Consent.

Founded five years ago, Mytrus has become a leader in innovative e-clinical technologies with a focus on accessibility and usability for patients in clinical trials. The company’s flagship product for direct to patient trials was first deployed by Pfizer in 2010 in the industry’s first clinical research study allowing patients to participate entirely from home.

Since then, Mytrus has worked to develop a pioneering line of new patient-focused products for electronic informed consent, patient data collection and research results reporting on clinical trials.

About Mytrus
Founded in 2009, Mytrus is a California-based clinical technology and services company which is revolutionizing traditional clinical trials with its simple, efficient, and patient-centered technologies. Mytrus streamlines the clinical trial process, dramatically improving patient recruitment timelines, increasing patient retention and reducing overall study costs for sponsors. At a time when bringing a drug to market can cost up to $1 billion, Mytrus provides solutions for pharmaceutical, biotech and device makers eager to find more cost effective ways to conduct research. Learn more about Mytrus at http://www.mytrus.com or find the company on Facebook and Twitter @mytrus.

About inVentiv Health
inVentiv Health, Inc., is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our client’s development and commercialization goals. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health’s clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. For more information, visit http://www.inVentivHealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of our acquisition of Catalina Health Resource, LLC and any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

Michael A. Griffith Named Executive Vice President of inVentiv Health

Griffith to Lead inVentiv’s Commercial and Consulting Segments Helping Pharmaceutical Companies Get to Market Faster and Optimize Revenue

BURLINGTON, Mass (March 10, 2014) – inVentiv Health, a life science knowledge and services company for the new health care environment, announced today the appointment of Michael A. Griffith as Executive Vice President. In this capacity, Griffith will head inVentiv’s Commercial and Consulting businesses and report to inVentiv Health CEO Paul Meister.

Griffith combines deep financial expertise with extensive knowledge of the pharmaceutical sector drawn from his leadership of three biotech and pharmaceutical companies over nearly two decades. His appointment demonstrates inVentiv’s commitment to innovation in commercialization services.

Most recently, Griffith was the Chief Executive Officer of Laureate Biopharma, a contract manufacturing organization providing outsourced biologics development and manufacturing services to the biopharmaceutical industry. Griffith also founded and served as Chief Executive Officer of Aptuit, with the mission of creating and engineering a better drug development process. He also served as Chairman and CEO of ChiRex, the foremost pharmaceutical process development company of its time.

“In every case, the companies Mike led grew significantly faster than the competition because clients wanted what these companies offered,” said inVentiv Health CEO Paul Meister. “The companies Mike runs do what they say they’re going to do and deliver what they promise. Mike’s strengths are building a winning culture, investing in talent and quality, delivery-to-promise and innovating in a complex regulatory and operational environment. This makes him a great fit for inVentiv Health.”

Griffith will head inVentiv’s commercial and consulting businesses that include Campbell Alliance, the nation’s leading biopharmaceutical management consulting firm; Adheris Health, the nation’s largest provider of patient adherence programs; Chandler Chicco Companies, the world’s largest pure-play healthcare communications firm and inVentiv Selling Solutions, the industry’s largest provider of outsourced clinical field and sales teams.

“inVentiv Health provides an opportunity for me to leverage all the skills I’ve acquired in finance, outsourcing, product development and commercialization,” Griffith said. “It is a pleasure to be working with a company built to change the game in the development and commercialization of treatments that improve patient outcomes worldwide.

“There is no other company with such a breadth and depth of capabilities enabling both full development and comprehensive commercialization and I look forward to contributing to the innovative, high-quality solutions inVentiv is creating to solve complex client needs.”

Griffith started his career in the financial services sector, working at both Bankers Trust Company and Credit Suisse First Boston. Additionally, he’s served on numerous Boards including Repligen Corporation and Centrue Financial Corporation. Griffith holds a Master of Management from the Kellogg Graduate School of Management at Northwestern University and received his B.S. degree from the University of Kansas.

About inVentiv Health
inVentiv Health, Inc. is a life science knowledge and services company purpose built for the new health care environment. Creating a new model for the new marketplace, inVentiv offers convergent services that accelerate the performance of companies developing and commercializing drugs to improve patient outcomes worldwide. In 40 countries around the world, inVentiv’s 12,000 employees work with more than 550 pharmaceutical, biotech and device companies, as well as companies that see health as a central part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health helps clients transform promising ideas into commercial reality. For more information, visit http://www.inVentivHealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of our acquisition of Catalina Health Resource, LLC and any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

Mytrus and Pfizer Win Best Practice Award for Strategic Innovation in Clinical Trials at Summit for Clinical Ops Executives (SCOPE)

Mytrus Shares Award with Pfizer for Electronic Informed Consent and Direct Patient Data Collection Technology for At-Home Clinical Research

BURLINGTON, Mass. (February 14, 2014) – inVentiv Health, offering best-in-class clinical, commercial and consulting services, today announced that Mytrus, Inc., a pioneer in electronic patient enrollment, has been recognized with a Best Practices Award from Clinical Informatics News for a project conducted for Pfizer, Inc.

Last spring, inVentiv Health took an equity position in Mytrus, Inc., as part of inVentiv’s strategic focus on increasing clinical trial efficiency. inVentiv has developed one of the industry’s broadest suite of technologies and services designed to speed patient and investigator recruitment, improve site feasibility and transform patient enrollment.

The award was presented to Mytrus during the 2014 Summit for Clinical Ops Executives (SCOPE) held last week in Miami. Established last year, the Best Practices Award from Clinical Informatics News recognizes clinical organizations for outstanding strategic innovation - partnerships, deployments, or collaborations that manifestly improve the clinical trial process. Nominees were judged by a panel that included two editors and five industry experts.

In the category of “Patient Data Management,” Mytrus and Pfizer received a joint award for a complete direct-to-patient clinical trial system, code-named “Apollo.” The technology used allowed patients in a trial to participate from home in everything from recruitment and informed consent to regular reporting of clinical data. The system also enabled the delivery of study data direct to participants upon the trial’s conclusion.

“inVentiv is fully aligned with our clients’ desire for faster drug development,” said Paul Meister, CEO of inVentiv Health. “We invested in Mytrus because of its pioneering use of technology in electronic patient enrollment and this award further validates the use of such technology as an industry best practice. We congratulate Mytrus and Pfizer for this well-deserved honor.”

Award finalists and winners were selected for their innovative use of clinical technologies including informatics, information technology, and knowledge management on a project or organizational level to achieve significantly improved results in clinical operations, clinical trial planning, or patient service. Other winners included Clinical Ink and Forte Research Systems.

Judges rated entries on innovation, importance, return on investment and likely industry impact, looking for examples that spotlighted the practical and positive deployment of novel technologies. Competitors included pharmaceutical companies, medical centers and clinical tools providers from around the world.

“We are honored to have worked closely with Pfizer in this important clinical trial which we believe will pave the way for many other new innovations in clinical research methods,” said Anthony Costello, CEO of Mytrus. “We are convinced that simplifying clinical trials for patients is a key to dramatically changing the time and cost of bringing new drugs to market.”

This is the second prestigious award in six months for Mytrus, which last August received Frost & Sullivan’s North American Product Leadership Award in Clinical Trials for their pioneering electronic informed consent application, enroll™. Frost & Sullivan, a respected global research organization that tracks more than 250,000 companies, compared Mytrus to other market competitors in a rigorous review that touched on several elements of product design, adoption, ease of use and market potential. Frost & Sullivan credited Mytrus with having developed a disruptive innovation that made the cumbersome, but critical process of informed consent simple and efficient for patients – while offering trial sponsors and regulators new opportunities to collect and track important informed consent data analytics.

Judges for this latest award included Clinical Informatics News editor Allison Proffitt; staff reporter Aaron Krol; Stephen Fogelson with Develotron; Naila Ganatra, Barnett International; Beth Harper of Clinical Performance Partners, Inc.; Joseph Kim with Shire Pharmaceuticals; and, Phillips Kuhl, Cambridge Healthtech Institute.

About Mytrus
Founded in 2009, Mytrus is a California-based clinical technology and services company built on the idea that modern technologies can enable people to safely and effectively participate in clinical trials without requiring them to live near a study center. The company’s proprietary methods can dramatically improve patient recruitment timelines, increase patient retention and reduce overall study costs for sponsors. Learn more about Mytrus at http://www.mytrus.com or find the company on Facebook and Twitter @mytrus.

About inVentiv Health
inVentiv is a leading global provider of best-in-class clinical, commercial and consulting services to the life science sector. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise allow us to serve as a strategic partner for companies facing a complex operating, regulatory and reimbursement environment. inVentiv clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients. For more information, visit http://www.inVentivHealth.com.

inVentiv Health's Digital+Innovation Partners with Appinions Analytics to Identify and Rank the Most Influential People in Healthcare

Proprietary Healthcare Influence Index Helps Optimize Communications Campaigns to Have More Impact and Achieve Greater Success in Reaching Patients

NEW YORK, NY (February 3, 2014) – inVentiv Health Communication’s digital consultancy, inVentiv Digital+Innovation, today announced a strategic alliance with influence analytics company Appinions to develop the first “Health Influence Index,” an innovative tool to improve multichannel, healthcare marketing campaigns.

The proprietary Healthcare Influence Index identifies those people, brands, companies and organizations whose opinions influence large groups of people, including patients. The Index uses data gathered from across the Web to create a proprietary ranking of the most influential voices in diabetes, cancer, depression, heart disease, multiple sclerosis and other diseases.

Built on more than a decade of research at Cornell University, Appinions’ proprietary software identifies, analyzes and measures influence based on content from more than six million sources, including traditional and digital media, blog and social media forums.

Digital+Innovation collaborated with Appinions to combine their technology with inVentiv’s broad global expertise in dozens of therapeutic areas to create the rankings of disease-specific influentials, the first of its kind in healthcare. The work was shaped by inVentiv’s core expertise in communications, drawn from its healthcare communications network the second largest healthcare communications business in the world.

“By combining inVentiv’s expertise with Appinions’ sophisticated analytics platform, our Digital+Innovation team has developed exclusive rankings to help clients identify spheres of influence that can be harnessed to educate stakeholders,” said Ritesh Patel, global head of inVentiv Digital+Innovation. “The result is more effective communications campaigns.”

inVentiv Health clients gain access to robust insights into how conversations around disease states are trending. They can identify who is most influential in online conversations concerning specific diseases and conditions. Such insights help companies more successfully reach patients and healthcare professionals with more relevant and tailored campaigns that produce measurable impact and more successful outcomes.

The first Index provides a snapshot of the most influential people on the subject of diabetes.

The Diabetes Influence Study identified, evaluated and compared the influence of advocacy and regulatory organizations, celebrities, pharmaceutical manufacturers and medical professionals. The ability to identify and leverage high-profile influencers in a health campaign can enhance efforts to change behaviors or raise awareness of treatments.

“We can’t imagine an industry where our data could have a more meaningful impact than healthcare,” said Larry Levy, co-founder and CEO of Appinions. “Our data, combined with inVentiv’s strategic communications expertise, will help clients design campaigns that are more effective, measurable and successful.”

Appinions technology already has been widely recognized and used outside the healthcare sector. The company recently was tapped by Forbes to conduct a second annual Chief Marketing Officer Influence study that identified the most influential CMOs and the subjects they were discussing. It provided Forbes’ readers with thought-provoking insights into current marketing topics and reinforced Forbes’ reputation for delivering quality content.

For access to the full Diabetes Influence Study, please visit http://goo.gl/juVoUg.

About Appinions
Appinions is the only opinion-powered influence marketing platform designed to give companies the unmatched ability to identify, analyze, engage, monitor and measure influencers. Built on more than a decade of Cornell University research, Appinions extracts and aggregates opinions from more than six million sources including blogs, social networks, forums, newspapers and magazine articles, thus providing a more complete picture of influence. Appinions helps today’s businesses insert trust into the purchase journey. For more information on the science of influence marketing, visit http://www.appinions.com.

About inVentiv Health Communications
inVentiv Health Communications (iHC) is the inVentiv Health division dedicated to delivering exceptional, global, multi-channel communications to organizations focused on health and wellness. The company’s unified offer brings together inVentiv Health’s advertising, public relations, public policy, market access, medical communications, media, creative, branding and digital services creating a “Super Agency” structure, enabling clients to excel in a rapidly changing environment. iHC’s strategic digital consultancy team, inVentiv Digital + Innovation, is comprised of healthcare, business-to-business, and consumer experts, all focused on delivering exceptional digital solutions.

For more information, visit http://www.inventivhealth.com/solutions/ihc/done_as_one.

inVentiv Health Extends Partnership Agreement with Swedish Firm NeuroVive Pharmaceutical AB

Mid-Size Pharmaceutical Companies With Promising Products Turn to inVentiv Health as a Strategic Partner for Expert Global Commercialization Services

BURLINGTON, Mass. (January 29, 2014) – inVentiv Health, offering best-in-class clinical, commercial and consulting services, announced today the extension of its partnership with NeuroVive Pharmaceutical AB, a publicly-traded Swedish biotech firm specializing in drugs that treat acute cardiovascular and neurological conditions.

inVentiv Health works with pharmaceutical and biotechnology firms to help define innovative alternatives to traditional development and commercialization models. inVentiv offers mid-size pharmaceutical and biopharmaceutical companies an expansive set of services that run from early-stage clinical development to full global commercialization. The breadth of inVentiv Health’s services is unique in the industry and includes comprehensive drug development, risk management, market access and reimbursement, launch, marketing communications, payer relations and patient outcomes.

NeuroVive, with a promising portfolio of mitochondrial drugs in development to treat acute cardiovascular and neurological conditions, has been evaluating various collaborations with large pharmaceutical companies and contract research organizations to reduce risk and increase cost efficiencies. They are currently in the planning stage for commercialization of their lead product, CicloMulsion®, now in a Phase III study to determine the drug’s effectiveness in reducing cardiac damage following stenting in heart attack patients.

NeuroVive is looking for a partner with an alternative business model that can commercialize CicloMulsion® and be leveraged to scale for future products. By working with inVentiv, mid-size pharmaceutical companies maintain more control and value with the ability to move faster to market.

“We’re big enough to step in and provide NeuroVive with virtually any service they require to develop and commercialize their compound, and we’re flexible enough to align with whatever they need to achieve their objectives,” said Dan Feldman, President of inVentiv Health Europe. “Pharmaceutical companies face a far more challenging market environment than ever before. Today’s market requires innovative strategic partnerships. inVentiv Health was created to provide this new model for the new marketplace.” NeuroVive already is accessing inVentiv services and recently completed a one-year regulatory consulting project with ParagonRx, inVentiv’s risk mitigation service. inVentiv will next be providing market assessment services through its consulting arm, Campbell Alliance. Campbell, a leading health care consulting firm, helps companies sell more effectively in an environment increasingly dominated by third-party payers.

NeuroVive and inVentiv also are discussing a broader expansion of the partnership to include future development and commercialization services for CicloMulsion®.

”We are very pleased to extend the collaboration with inVentiv Health, an important step in preparing the market for launch of CicloMulsion® in Europe and, later, in the United States,” said Mikael Brönnegård, CEO of NeuroVive Pharmaceutical AB. “inVentiv Health´s commercial services will provide a valuable platform for optimal market penetration at later stages and when approaching the launch and marketing of the product.”

ABOUT INVENTIV HEALTH
Our broad range of services and our global scale, represented by approximately 12,000 employees supporting clients in more than 70 countries, allow us to serve as a critical strategic partner for pharmaceutical, biotechnology, medical device and diagnostics, and health care companies in their dynamic and rapidly changing regulatory and commercial environments. We serve more than 550 client organizations, including all 20 of the largest global pharmaceutical companies. For more information, visit http://www.inVentivHealth.com.

ABOUT NEUROVIVE PHARMACEUTICALS AB
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive’s research programs also include products for the treatment of anti-viral indications (Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for cellular protection and treating mitochondria-related energy regulation diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.

Media and investor relations questions to:
Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 6221 or ir@neurovive.se

Please also use the above contact if you wish to arrange an interview with NeuroVive’s CEO, Mikael Brönnegård.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of our acquisition of Catalina Health Resource, LLC and any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from health care reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the health care and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Health Leverages Advanced Digital Technology to Slash the Time Required to Conduct Feasibility Studies

Partnership with ViS Research Has the Potential to Cut in Half the Time Needed to Conduct Clinical Trial Feasibility Studies Through Process Innovation

BURLINGTON, Mass. (January 23, 2014) – inVentiv Clinical Trial Recruitment Solutions (iCTRS), an inVentiv Health company leading the biopharmaceutical sector in reducing the time to the start of clinical trials, announced today that the process innovations offered by its partnership with ViS could cut in half the time required to conduct feasibility studies.

The most recent report issued this month by the Tufts Center for the Study of Drug Development noted that the drug development model had not fundamentally changed in years, and that the future success of pharmaceutical companies will depend in part on their ability to adopt greater efficiencies and best practices.

One area ripe for improvement is clinical site feasibility in the planning for trial. Even though the selection of sites capable of enrolling patients is a critical step to ensuring the smooth operation of a clinical trial, site selection is fraught with inefficiencies. An estimated $10 billion a year is wasted because of poor site selection.

The use of technology is critical to process improvement in feasibility. To demonstrate the potential for savings, iCTRS took data from 100 feasibility studies conducted by inVentiv, and analyzed the time required to perform each of the individual tasks involved in such studies. The company then looked at how much time the application of ViS technology could save for each task. Cumulatively, the efficiencies offered by ViS cut the total feasibility study hours by 54% -- while delivering better quality. Additional time savings potentially could be realized by applying other technologies in the iCTRS portfolio.

ViS Research, creator of the world’s first comprehensive online feasibility platform, gives trial planners better, real-time data for the efficient evaluations of locations, sites, investigators, and networks for possible inclusion in clinical trials. The ViS global map of clinical research infrastructure, assembled over a decade of research, includes detailed and vetted information on more than 400,000 disease-specific centers.

Research centers and investigators can efficiently share their capabilities by uploading a profile on the digital platform where the information can be stored and updated regularly, eliminating redundant paper questionnaires. Up until now, many investigators chose to not participate in feasibility because it was so difficult. Instead of answering the same questions multiple times, investigators can now build upon the existing profile and focus on answering protocol-specific questions that will help differentiate their site from another site being considered.

For trial sponsors, the ViS profile provides answers to 85% of the routine questions they normally ask. Sponsors can review the profiles, use the platform to contact investigators and gather additional information. High-quality analytics and visualization tools allow sponsors to quickly and easily compare sites and feasibility data for accelerated selection of sites that are properly equipped, staffed, and ready to be activated for study participation.

“At the end of the day, this is all about doing feasibility studies better, faster and getting drugs and devices into quality clinical trials at an accelerated rate,” said Ramita Tandon, senior vice president and general manager for iCTRS. “In the next phase of development on the ViS platform we’ll accelerate processes even more.”

iCTRS this month launched its own proprietary network on the ViS platform, using the social media functions that enable far easier networking. iCTRS is the only service provider with rights to use the ViS database for building its own social network. Investigators will have access to information on new trial opportunities posted by iCTRS, while sponsors can share information on upcoming trials and more closely interact and collaborate with investigators. iCTRS and ViS are developing additional, exclusive functionality, including automating the workflow process for confidential disclosure agreements (CDA) and the onboarding of clinical trial investigators. Streamlining and simplifying processes will help attract and retain more high-quality investigators who can enroll patients, conduct efficient trials and move the start-up phases of the drug development process into the 21st century.

iCTRS was specifically created to integrate a game-changing set of global capabilities to accelerate trials in a predictable and cost-efficient way. “It’s all about hitting timelines, and it starts with feasibility. This is the first place we challenge assumptions about old ways of doing trials and find efficiencies through technology to do things better,” Tandon said.

About inVentiv Health
Our broad range of services and our global scale, represented by approximately 12,000 employees supporting clients in more than 70 countries, allow us to serve as a critical strategic partner for pharmaceutical, biotechnology, medical device and diagnostics, and healthcare companies in their dynamic and rapidly changing regulatory and commercial environments. We serve more than 550 client organizations, including all 20 of the largest global pharmaceutical companies. For more information, visit http://www.inVentivHealth.com.

About ViS Research (ViS)
The ViS online feasibility platform is the first to integrate analytics about investigators, sites, networks, and trial locations, while enabling engagement between trial planners and sites. Trial planners use interactive visualizations to navigate the intricate, disease-specific decision matrix to immediately gather feasibility information from 400,000+ disease-specific research sites and 360,000+ investigators. ViS helps these investigative sites by decreasing their administrative burden related to feasibility questionnaires, while enabling them to efficiently display their disease-specific capabilities, at no cost. The end result is that optimal decisions can be reached using a small fraction of the time and cost incurred through conventional methods. ViS Research was created as a global enterprise in 2010, with trial planning experts in four continents. More information at http://www.visresearch.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of our acquisition of Catalina Health Resource, LLC and any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

PharmaTimes Recognizes inVentiv Health's Litmus Medical Marketing and Education as Communications Agency Team of the Year

London Team Is Part of inVentiv Medical Communications’ Innovative Global Network of Peer-to-Peer Medical and Scientific Communications Experts

BURLINGTON, MASS. (December 12, 2013) – Litmus Medical Marketing and Education, the London-based unit of inVentiv Medical Communications, has been named PharmaTimes Communications Agency Team of the Year, one of the United Kingdom’s most prestigious industry awards.

Litmus took top honors in the “NHS Challenge” designed specifically for agencies with expertise in the UK’s National Health Service. The PharmaTimes Marketer and Communications Team awards, now in its 20th year, recognize innovative, competency-based programs. To participate, communications teams must be nominated by their clients for the work they do over a year.

“This is a fantastic honor for the Litmus team, but the award is especially meaningful to us because we were nominated by clients who we work with every day,” said Elaine Ferguson, Global Managing Director of inVentiv Medical Communications. “Working for great clients, excelling in what we do and winning this sort of recognition encourages us to do even more.”

To win the award, five finalists compete in a simulated pitch challenge with just two hours to respond to a brief and 15 minutes to present their recommendations. The challenge was crafted by senior marketing and healthcare leaders to gauge key agency capabilities.

inVentiv Medical Communications (iMC) has created one of the industry’s largest global network of experts in peer-to-peer medical and scientific communications. In addition to Litmus in London, iMC’s network includes offices in Munich, Paris, Shanghai, Tokyo, Dallas and Philadelphia. iMC’s deep understanding of healthcare professionals and health systems throughout the world mean clients benefit from both a global perspective and local insights. The result is rich, persuasive communications that educate and influence the clinical and payer audiences the healthcare industry must reach for successful commercialization.

iMC also is breaking new ground in integrating late-stage clinical development with commercialization teams through an approach called Evidence Catalytics, designed to meet the growing need among biopharmaceutical companies for timely, real-world evidence of a product’s value. Healthcare professionals and governments/payers increasingly require more than evidence that a drug works and appears relatively safe in carefully controlled clinical studies. They need to be convinced of the clinical, economic, real-world value and how it is better than other drugs and existing standards of care.

“The approach we’re taking through Evidence Catalytics allows us to act as a catalyst for accelerating commercial success by planning the needs of a product in the real world in advance and efficiently generating the evidence required to communicate with stakeholder in the marketplace,” Ferguson said. “We are finding tremendous interest in this approach among our clients.”

For a full recap of the competition and all winners, visit PharmaTimes Online.

About inVentiv Medical Communications
iMC is uniquely focused on facilitating peer-to-peer and scientific communications. Its use of a full range of communications channels is bolstered by employing cutting-edge digital technology. Working in close partnership with clients, iMC provides medical strategies for advisory boards, medical content development and publication, virtual and in-person events and communications between physicians, nurses and healthcare professionals. The goal is to build relationships, foster understanding and encourage collaboration between the biopharmaceutical industry and medical/healthcare professionals.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to the life sciences industry. inVentiv offers convergent services that accelerate the performance of companies working to improve human life. In 40 countries around the world, inVentiv’s 12,000 employees work with more than 550 pharmaceutical, biotech and device companies, as well as companies that see health as a central part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health helps clients transform promising ideas into commercial reality. For more information, visit http://www.inVentivHealth.com.

inVentiv Health Hires Senior Life Sciences Executive to Oversee Expansion of Multi-faceted Operations in India

Anita Tripathy Named President of inVentiv Health India

BURLINGTON, Mass. – November 25, 2013 – inVentiv Health, offering best-in-class clinical, commercial and consulting services to the biopharmaceutical industry, has named a senior executive in India’s life sciences industry to lead its expanding operations in India.

Anita Tripathy joins inVentiv Health from Capgemini, India, where she served on the leadership team of the global provider of consulting, technology and outsourcing services. At inVentiv Health, as President, India, she will be responsible for the management, development and growth of all business units in India across inVentiv’s Clinical and Commercial segments.

“By enhancing our organization in India and our service offerings there, inVentiv is prepared to better meet our customers’ need for more cost-effective research, data services and strategic outsourcing,” said Paul Meister, CEO of inVentiv Health. “India remains a top choice among global pharmaceutical and biotech companies on the skills-to-cost scale, and Anita’s deep understanding of India, IT and the life sciences sector will support our growth.”

India is a key market for inVentiv’s growth plans in Asia. With significant Indian operations already in place, the Company has an excellent platform for a new leader to expand both inVentiv’s customer base and the development of new services.

She will be based in Mumbai and report to inVentiv Health Executive Vice President Ray Hill.

At Capgemini, Anita Tripathy led a strategic cluster of IT products for the European market. While at Cognizant earlier in her career, she led the Strategic Business Unit for Life Sciences in India. She orchestrated teams based out of India, China and Argentina, delivering services across three continents, North America, Europe and Asia Pacific.

Before transitioning to the life sciences industry, she worked in ERP applications for KPIT Cummins Infosystems Ltd., and at Satyam Computer Services Ltd. She also worked in Pune at Nestle India as a systems analyst, and at ICIM Ltd as a senior systems engineer.

She holds a Bachelor’s degree in Chemistry from Berhampur University and a Master’s in Computer Applications from the Regional Engineering College, Rourkela, Orissa, India.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 12,000 employees help more than 550 clients rapidly transform promising ideas into commercial reality. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inVentivHealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of our acquisition of Catalina Health Resource, LLC and any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

Paul Mignon and inVentiv Health Receive 2013 Award of Hope for Corporate Leadership from Rutgers Cancer Institute of New Jersey

Mignon, President of inVentiv Selling Solutions, Recognized for Commitment to Serving People with Cancer in his Home State of New Jersey

BURLINGTON, MASS. – November 1, 2013 – inVentiv Health, offering best-in-class clinical, commercial and consulting services, announced today that the company and a dedicated inVentiv executive have been awarded the 2013 Award of Hope for Corporate Leadership from Rutgers Cancer Institute of New Jersey.

As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey is dedicated to improving the prevention, detection, treatment, and care of patients with cancer, through the transformation of laboratory discoveries into clinical practice. It’s Award of Hope has been given over the last 16 years to recognize those who have demonstrated untiring leadership and a deep commitment to serving the needs of people with cancer.

Mignon, President of inVentiv Health Selling Solutions, was introduced to the Cancer Institute in 2001 when a close friend was diagnosed with cancer. Witnessing his friend’s battle first-hand inspired Mignon to get involved. Over time, he became an ambassador for the Cancer Institute, personally and professionally, helping to raise funds that enabled the growth of the Institute into one of the nation’s leading cancer centers.

He established a partnership between the Institute and inVentiv, recognizing that both organizations in different ways shared an interest in delivering extraordinary outcomes to patients. inVentiv has been a regular contributor to the Institute’s work, while the Institute has helped inVentiv by providing cancer education for employees. The partnership has endured for nearly a decade.

“We are proud of Paul and grateful to him for suggesting ways in which we could partner in supporting one of New Jersey’s most distinguished health care institutions,” said Paul Meister, CEO of inVentiv Health. “We are very honored to be recognized in this way.”

Mignon also has volunteered as a Trustee of the Cancer Institute Foundation and is currently a member of the Rutgers Cancer Institute Director’s Advisory Council.

The award was presented at a gala dinner on October 24th where they were recognized for leadership, generosity and dedication to improving human life.

In receiving this award, Mignon and inVentiv join the ranks of a number of distinguished individual and corporate winners including Johnson & Johnson and Unilever, New Jersey Governor Christine Todd Whitman and John R. Whitman and Mary Lasser and the Thomas A Lasser Foundation.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to the life sciences industry. inVentiv offers convergent services that accelerate the performance of companies working to improve human life. In 40 countries around the world, inVentiv’s 12,000 employees work with more than 550 pharmaceutical, biotech and device companies, as well as companies that see health as a central part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health helps clients transform promising ideas into commercial reality. For more information, visit http://www.inVentivHealth.com.

inVentiv Health Acquires Catalina Health to Become Nation's Largest Provider of Patient Adherence Programs

Two Leaders in Medication Adherence and Education Join Forces to Deliver Tailored, Multi-Channel Communications Across the Continuum of Care to Millions of Patients Nationwide

BURLINGTON, Mass. – October 31, 2013 –inVentiv Health, offering best-in-class clinical, commercial and consulting services, announced today that it has acquired Catalina Health, a subsidiary of Catalina, and combined the organization with Adheris, an inVentiv Health company.

With this acquisition, inVentiv Health’s Adheris becomes the nation’s largest provider of tailored, direct-to-patient medication adherence programs. Medication adherence programs, that include refill reminders and disease education, help millions of chronically ill people stay on their doctor-prescribed treatment, saving the healthcare system money and improving patient outcomes.

Both Adheris and Catalina Health work through pharmacies across the country to deliver adherence communications to millions of people. By joining forces, Adheris now has an unmatched reach through a network of more than 40 pharmacy partners composed of 30,000 pharmacies representing 65% of all retail prescriptions. Meanwhile, Adheris continues to rapidly grow its physician office network as a complement to its pharmacy network, allowing the company to reach even more patients with personalized communications across the continuum of care.

“Improving patient outcomes is our number one priority,” said Mark Dmytruk, President, inVentiv Health Patient Outcomes. “A coordinated adherence approach – reaching individual patients across multiple touch points with customized messages based on predictive analytics – improves adherence in ways other organizations simply cannot match.”

Adheris’ enhanced services will allow patients to receive communications in the doctor’s office from their trusted healthcare provider, followed by face-to-face communication with their pharmacist. Later, when it is time to refill their prescription, Adheris can send patients a message from their pharmacy reminding them of the importance of staying on the medication their doctor has prescribed. Communications can be delivered through multiple channels, including mobile.

By combining its expertise in predictive analytics with Catalina Health, Adheris will offer even stronger and more effective messaging based on a more robust understanding of consumer preferences and needs. The acquisition also allows Adheris to provide clients with a single vendor for the purchase of multiple services, further streamlining the delivery of effective adherence communications.

Adherence programs have demonstrated value in improving individual health and saving the healthcare system money. At a time when federal, state and private healthcare programs are seeking ways to reduce costs and improve care, adherence programs are increasingly important and further the goals of the Affordable Care Act.

“Over the past year, we’ve seen growing client demand for coordinated patient messaging and an increased focus on patient-centric outcome strategies,” said Dmytruk. “The acquisition improves our ability to deliver exactly what our clients need.”

Renee Selman, President of Catalina Health, will lead the combined business. Prior to joining Catalina Health, Selman served in various leadership positions with Johnson & Johnson, including Worldwide President of Ethicon Women's Health and Urology. Jim Rotsart will move from GM/Executive Vice President of Adheris to become EVP of inVentiv Health Patient Outcomes.

Catalina Health will now operate under the Adheris name. For more information, visit www.adheris.com.

About Adheris, Inc.
An inVentiv Health company, Adheris is the nation’s largest provider of tailored, direct-to-patient medication adherence programs. Medication adherence programs, that include refill reminders and disease education, help millions of chronically ill people stay on their doctor-prescribed treatment, improving patient outcomes. Adheris’ unmatched network, of more than 40 pharmacy partners composed of 30,000 pharmacies, represents 65% of all retail prescriptions. Its groundbreaking, multi-channel programs are HIPAA compliant and are proven to influence positive behavior change for millions of patients across the continuum of care.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to the life sciences industry. inVentiv offers convergent services that accelerate the performance of companies working to improve human life. In 40 countries around the world, inVentiv’s 12,000 employees work with more than 550 pharmaceutical, biotech and device companies, as well as companies that see health as a central part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health helps clients transform promising ideas into commercial reality. For more information, visit http://www.inVentivHealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Health Opens State-of-the-Art Office in Maidenhead, United Kingdom, to Respond to Accelerated Demand for Services in Europe

New Office Becomes UK-Operating Hub Supporting European Expansion

LONDON (October 18, 2013) – inVentiv Health, offering best-in-class clinical, commercial and consulting services, has consolidated three Greater London offices into a single, state-of-the-art office space in Maidenhead, Berkshire. The new office will allow the company to better service its European customer base.

The newly-constructed, built-to-suit space allows for improved integration and knowledge-sharing across inVenitv’s clinical, commercial and consulting businesses. The three-storey building initially will house 180 employees with space to accommodate many more over the coming months.

Theresa May, Member of Parliament for Maidenhead and Home Secretary, attended a ribbon- cutting ceremony commemorating the opening of the new office. inVentiv executives joining her at the event included Susan C. Stansfield, Executive Vice President, Global Clinical Operations and Project Management Office; Stephen Preece, Senior Vice President, Human Resources; and Steve Mitchell, Senior Director, Clinical Data Management.

Following the ribbon cutting, the Home Secretary spoke to a large group of inVentiv employees.

Paul Meister, Chairman and Chief Executive Officer of inVentiv Health, said the new office was “an important milestone in the expansion of our company as it allows us to successfully meet the needs of our clinical, commercial and consulting workforce. inVentiv’s global footprint continues to expand and the Maidenhead office will play a central role.”

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to the life sciences industry. inVentiv offers convergent services that accelerate the performance of companies working to improve human life. In 40 countries around the world, inVentiv’s 12,000 employees work with more than 550 pharmaceutical, biotech and device companies, as well as companies that see health as a central part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health helps clients transform promising ideas into commercial reality. For more information, visit http://www.inventivhealth.com.

inVentiv Health Communications Adds Global Digital Expertise to Dramatically Improve Physician-Patient Communications

Emma D’Arcy Joins inVentiv Health’s London Digital Team as Head of Participatory Medicine; Ben Atkins Joins Chandler Chicco Companies as Chief Digital Officer in the West

BURLINGTON, MASS. – October 9, 2013 The global communications division of inVentiv Health, offering best-in-class clinical, commercial and consulting services, today announced the appointment of two social media veterans to address the dramatic changes taking place in the way patients and physicians communicate.

Emma D’Arcy has joined inVentiv Health Communications’ Digital+Innovation team in London as head of Participatory Medicine. Participatory Medicine is an emerging model of care that promotes health care professionals and patients working in full partnership, using contemporary communications channels to increase the patient’s participation in their health care decision making. D’Arcy will work with clients to apply principles of Participatory Medicine to increase the success of new product launches.

D’Arcy is a medical biochemist who is currently conducting research on the impact of social media on the practice of medicine. A seasoned writer with 18 years of experience in the pharmaceutical industry, she is a frequent speaker and organizer of patient-centric conferences and has been published widely on the impact of digital communications on health care.

Ben Atkins, located in Los Angeles, will co-lead the growing digital practice of Chandler Chicco Companies to drive innovation, best practices, and digital/social integration across Chandler Chicco’s agencies. Atkins’ focus is on designing social experiences that help brands and organizations promote behavior change, and through his work clients better integrate their digital initiatives across corporate, product, physician and patient communications.

Prior to Chandler Chicco Companies, Atkins was at Amgen, where he worked as corporate communications director of digital and social media. In this role, Atkins led oversight and execution of Amgen’s web strategy, including the use of measurable digital and social technologies. Atkins also held roles of increasing responsibility at Novartis, including head of news and social media communications and global pharma news manager.

“Patients today are supporting one another on social networks, and healthcare professionals are becoming increasingly engaged with mobile communications and social media,” said Robert Chandler, President, inVentiv Health Communications. “Connecting these stakeholders through digital and social channels is essential to facilitating meaningful interactions to improve patient outcomes.”

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to the life sciences industry. inVentiv offers convergent services that accelerate the performance of companies working to improve human life. In 40 countries around the world, inVentiv’s 12,000 employees work with more than 550 pharmaceutical, biotech and device companies, as well as companies that see health as a central part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health helps clients transform promising ideas into commercial reality. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Health Names President for Europe and Executive Vice President for Asia to Lead Management of Growing Business

Dan Feldman Takes Reins of inVentiv Health Europe While Stephen J. Walter Joins to Lead ASEAN Countries, China and Korea

BURLINGTON, MASS., September 26, 2013 – inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, announced today the creation of two new positions to lead its growing business in Europe and Asia.

Dan Feldman, who established and led inVentiv’s very successful operation in Japan, will take on the new position of President of inVentiv Health Europe. The position will oversee the growth of business across all inVentiv Health segments – clinical research, commercialization and consulting – and will lead development of inVentiv’s unique approach to convergent services.

“In only two years, Dan established inVentiv’s outsourced sales force in Japan and grew it to become the second largest such business in the country, before moving on to establish our clinical and consulting services there,” said Paul Meister, CEO of inVentiv Health. “Dan will now be able to help our Japanese clients expand in Europe, as well as assist with our growing roster of European clients requiring services that accelerate delivery of therapies to market.”

Feldman will lead regional business development, promote inVentiv’s “Done as One” approach to convergent services and assure the continued growth of inVentiv’s European footprint.

Stephen J. Walter will join the company as Executive Vice President for Asia. Walter formerly served as Managing Director for Merck Sharpe & Dhome in Vietnam and Cambodia. Previously, he worked as General Manager and Vice President of Consulting and Services for IMS Health, based in Singapore. For Bristol-Myers Squibb, he helped launch Entecavir in the Asia Pacific region and then served as Regional Director of Business Development.

In his new role, Walter will oversee growth and management of all inVentiv Health business throughout the region, including the expansion of inVentiv’s clinical research capabilities in China.

“We are fortunate to have found someone who combines a broad knowledge of the entire Asian market with a deep understanding of what biopharmaceutical companies need in developing drugs and shepherding them through commercialization,” Meister said.

Walter, who will be based in Shanghai, will oversee inVentiv operations in the ASEAN nations, Australia and New Zealand, in addition to China and Korea. He will also assume responsibility for Japan at the end of this year, when he takes the reins from Feldman.

Walter, who won a post-graduate fellowship from the Australian Board of Trade for work in Vietnam, holds an MBA from the University of New South Wales in Sydney and a Bachelor of Science degree in microbiology and genetics from the University of Melbourne.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to the life sciences industry. inVentiv offers convergent services that accelerate the performance of companies working to improve human life. In 40 countries around the world, inVentiv’s 12,000 employees work with more than 550 pharmaceutical, biotech and device companies, as well as companies that see health as a central part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health helps clients transform promising ideas into commercial reality. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Health Clinical Launches Physician Network for Late-Stage Research

New Web-Based Tool Engages Physicians to Accelerate Study Enrollment

PRINCETON, NJ, September 24, 2013 – inVentiv Health Clinical, a leading global supplier of drug development services, today announced the launch of an innovative, web-based network to efficiently connect physicians interested in participating in late-stage research to appropriate clinical trials.

The inVentiv Physician Network (inVentivDocNet.com), a crowdsourcing tool, promises to help research sponsors accelerate study enrollment. It is part of inVentiv Health’s broad strategic investment in innovation to speed clinical trials.

“We believe physicians will find this a valuable new channel for accessing ‘real-world’ research opportunities,” said Jeff Trotter, inVentiv Health Clinical Executive Vice President – Late Stage. “The inVentiv Physician Network welcomes virtually any clinician who seeks to participate in observational research, including patient registries, safety surveillance programs, postapproval safety studies, and other noninterventional and quality-of-life studies.”

By joining the network, physicians can find easy-to-manage research opportunities involving approved products used in everyday practice. Sponsors can access the busiest and most relevant practicing physicians for their studies, accelerating both site and patient enrollment. Together, physicians and sponsors can generate real-world information that is critically important in establishing the value of medical treatments and procedures.

The inVentiv Physician Network complements inVentiv’s other innovations in clinical trial recruitment. inVentiv Clinical Trial Recruitment Services (iCTRS) uses behavioral research, proprietary data, and cutting-edge technology to improve feasibility, enrollment, and patient recruitment. Mytrus Inc., in which inVentiv has acquired an equity stake, has pioneered electronic informed consent to improve trial efficiency and patient retention.

“With the inVentiv Physician Network we bring more and more physicians the opportunity to contribute vital new data to the medical community by participating in important new studies that capture real-world patient experiences and clinical outcomes,” Trotter said.

inVentiv aims to enroll tens of thousands of physicians in the year ahead through an online promotional campaign aimed at practitioners in virtually all therapeutic areas. The network makes it convenient for physicians to stay abreast of late-stage research and to discover studies that suit their patients and practices. All visitors to the Physician Network website are able to view a current list of studies available for participation. Once a member, physicians may select one or more studies, and connect with the inVentiv Health Clinical team to qualify for participation. For more information and to join the inVentiv Physicians Network visit: inVentivDocNet.com

About inVentiv Health Clinical
inVentiv Health Clinical is a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, offering therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical services, and strategic resourcing from a single clinical professional to an entire functional team. With 7,000 passionate employees operating in 70 countries, inVentiv Health Clinical works to accelerate high quality drug development programs of all sizes around the world. http://www.inventivhealthclinical.com

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to the life sciences industry. inVentiv offers convergent services that accelerate the performance of companies working to improve human life. In 40 countries around the world, inVentiv’s 12,000 employees work with more than 550 pharmaceutical, biotech and device companies, as well as companies that see health as a central part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health helps clients transform promising ideas into commercial reality. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Clinical Trial Recruitment Solutions Partners with Pioneering Firm to Revolutionize Clinical Trial Site Evaluation

iCTRS Partners with ViS Research to Help Trial Planners Benefit from a Better, More Efficient Site Selection Process to Accelerate Development of Much-Needed Medicines

BURLINGTON, Mass., September 18, 2013 – inVentiv Clinical Trial Recruitment Solutions (iCTRS), offering solutions to overcome the costly obstacles that delay clinical trials, announced today a strategic partnership with ViS Research to revolutionize and speed the antiquated system of clinical trial site evaluation.

Developing a drug can cost more than $1 billion, with a single clinical trial running more than $100 million. Proper planning is key to efficiently using R&D investment and avoiding delays in getting new medicines to market. Yet about 80% of clinical trials are delayed because of unfulfilled enrollment.1 iCTRS has pulled apart and analyzed each obstacle in clinical trial planning to improve the process.

The partnership with ViS addresses the key problem of clinical trial site evaluation – trial planners simply don’t have adequate analytics about research centers and locations where centers operate. Information is often inaccurate and outdated – or simply does not exist. To find the right trial site, across more than 400,000 research centers worldwide, trial planners send out lengthy feasibility questionnaires, often on paper, that are frequently never filled out or returned. An estimated $10 billion a year is wasted because of poor site selection – the failure to match trial planners with appropriate, effective research sites.

Through its partnership with ViS, iCTRS brings an interactive navigation system to this clinical research universe, so that trial planners can quickly match their needs with the disease-specific capabilities of individual research centers. They can quickly and efficiently evaluate all the relevant analytics – such as local patient population, research activity, infrastructure, personnel, timelines – from the country level through state, city, postal code, all the way down to what is inside the research center facilities.

“We are committed to accelerating clinical research through breakthrough innovation, and this partnership offers trial sponsors the fastest most sophisticated way of ensuring research sites are properly equipped, staffed and ready to be processed for rapid activation,” says Ramita Tandon, senior vice president and general manager for iCTRS. “We are looking forward to building on the remarkable platform and database that ViS already has created.”

ViS experts generate analytics relevant to the locations where centers operate, through sophisticated algorithms and semantic technologies. The resulting analytics are validated by local experts and integrated with crowd-sourced input from clinical research centers through ViS’ social network, where centers upload their disease-specific profiles. ViS' collaborative analytics approach integrates large amounts of data to provide up-to-date analytics, while enabling research centers to securely and efficiently showcase their disease-specific capabilities to trial planners.

Under the partnership agreement, and building upon ViS research platform, iCTRS and ViS will co-develop advanced, proprietary features for the platform that include automation of the Confidential Disclosure Agreement workflow and final sign-off, and enhanced analytical capabilities to rapidly compare feasibility information between sites.

“The entire feasibility process has needed revamping, and in partnering with iCTRS we expand our ability to deliver greater efficiency to the industry through innovative technologies in analysis, visualization, and networking,” said Fabio Thiers, MD, PhD, ViS founder and CEO, a Harvard/MIT physician-scientist and pioneer in clinical research analytics. “We believe the use of these technologies could reduce waste in global clinical research by 10-15%.”

The ViS partnership is the latest in a series of innovative partnerships announced by iCTRS that include Medikly, PatientsLikeMe.com, and Mytrus, Inc., in which inVentiv Health holds an equity stake – all designed to get much-needed medicines to market faster and more cost efficiently.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to the life sciences industry. inVentiv offers convergent services that accelerate the performance of companies working to improve human life. In 40 countries around the world, inVentiv’s 12,000 employees work with more than 550 pharmaceutical, biotech and device companies, as well as companies that see health as a central part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health helps clients transform promising ideas into commercial reality. For more information, visit http://www.inventivhealth.com.

About ViS Research (ViS)
The ViS online feasibility platform is the first that allows trial planners to use interactive visualizations to navigate the intricate, disease-specific decision matrix to immediately gather feasibility information from 400,000+ disease-specific research sites and 320,000+ investigators. ViS helps these investigative sites by decreasing their administrative burden related to feasibility questionnaires, while enabling them to efficiently display their disease-specific capabilities, at no cost. The end result is that optimal decisions can be reached using a small fraction of the time and cost incurred through conventional methods. The ViS Research Institute was created as a global enterprise in 2010, with trial planning experts in four continents. More information at http://www.visresearch.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Health and Mehlman Vogel Castagnetti Partners Launch Breakaway Policy Strategies to Help Clients Anticipate Changes to U.S. Health Policy

Breakaway’s Sophisticated, Customized Counsel Helps Clients Thrive Amid Change

BURLINGTON, Mass., September 16, 2013 – inVentiv Health, offering best-in-class clinical, commercial and consulting services, today announced the launch of its new policy arm, Breakaway Policy Strategies, a joint venture between inVentiv and the partners of Mehlman Vogel Castagnetti, a leading, bipartisan lobbying firm.

Breakaway helps companies address the diverse challenges posed by a nationwide healthcare system being reshaped by increasing government regulation and dramatic shifts in the private healthcare market. The firm provides strategic analysis and policy guidance to help healthcare stakeholders navigate transformative changes arising from decisions made daily by Federal and state policymakers.

Changes already underway include the emergence of Accountable Care Organizations, Health Insurance Exchanges and bundled payment arrangements. Additional changes will take effect next year, leading to dramatic expansions of health coverage for American consumers and increasing government influence over hospitals, health plans, employers, doctors, patients, employers, biopharmaceutical firms, and device companies.

“Now more than ever, clients must have a sophisticated understanding of the sweeping changes taking place in America’s healthcare system,” said Paul Meister, CEO of inVentiv Health. “Navigating this new landscape requires seasoned experts with historical knowledge, a deep understanding of political context, and the ability to anticipate what’s next. Through Breakaway, we offer experts with an unmatched level of health policy expertise.”

The collaboration expands inVentiv’s presence in Washington, D.C. and enhances its broad portfolio of services. For Breakaway, the investment enables an expansion of research capabilities and the addition of top-notch talent.

Breakaway’s team combines extensive experience in the public sector with equally deep private sector expertise. The team has extensive know-how in private health insurance markets, private programs in Medicare and Medicaid, and emerging delivery models. Drawing on all this experience, Breakaway delivers unparalleled analysis, strategic solutions and practical advice to guide clients through changes in how healthcare will be delivered, consumed and paid for.

Dean Rosen, one of the nation’s top policy experts and former health policy director for Senate Majority Leader William H. Frist, will serve as Breakaway’s President and Chief Executive Officer. While working with Frist, Rosen helped shepherd through Congress The Medicare Prescription Drug Improvement and Modernization Act of 2003. He also played a major role in advancing many other major health reform laws during his career in public service, including the Health Insurance Portability and Accountability Act (HIPAA) and The Patient Safety and Quality Improvement Act. Rosen also was Senior VP of Policy and General Counsel at Health Insurance Association of America, and worked on the House Ways and Means Committee. He will continue in his role as a partner at Mehlman Vogel Castagnetti.

“Federal and state policymakers are reshaping the future of healthcare daily,” said Rosen. “No matter what policies are written or how healthcare may change, Breakaway understands policy details, knows the decision makers, and is closely connected to the system in which these decisions are taking place.”

Breakaway closely tracks policy developments at the state and federal level, providing timely, comprehensive reports, including the Weekly Breakdown Newsletter, the Monthly Affordable Care Act (ACA) Implementation Guide, and in-depth analysis of topics such as Medicare Physician Payment Reform. Beyond comprehensive research, Breakaway’s approach to policy analysis provides strategies for the real world, tailored to individual client challenges.

Joining Rosen at Breakaway is Rick Smith, former Executive Vice President for Policy and Research at the Pharmaceutical Researchers and Manufacturers of America (PhRMA) and Vice President for Research and Policy at America’s Health Insurance Plans (AHIP). Also on board is Margaret Nowak, former head of policy at Walgreens, Medicare analyst at the Congressional Budget Office and Director at Avalere Health. Colette Desmarais, a former top staffer for Senator Charles Grassley (R-IA) and Deputy Director at AHIP’s Public Programs Policy Unit, also is part of the Breakaway team. Complementing this team is an extended staff of lawyers, budget analysts, specialists in government programs, and health policy experts who can swiftly assist stakeholders in navigating new models, rules and regulations.

Breakaway’s services complement those of inVentiv Health’s premier public relations firm, Chandler Chicco Companies, the world’s largest pure-play healthcare communications group. Chandler Chicco recently appointed Heather Gartman as its new D.C. office head. A two-decade public relations veteran, Gartman was previously at Ruder Finn and Zeno Group.

When coupled with inVentiv’s clinical, market access, adherence and communications expertise, Breakaway can design strategic solutions to help clients with policies that impact reimbursement, access to products and improved patient outcomes.

About Breakaway Policy
Since the beginning of 2013, Breakaway has been providing analytical support and strategic counsel to Fortune 500 health care companies, as well as health care trade associations and foundations. A health policy joint venture between inVentiv Health and the partners of the bipartisan lobbying firm Mehlman Vogel Castagnetti, Breakaway provides research, analysis, practical advice, and strategic solutions to help a wide range of healthcare stakeholders navigate the transformative changes taking place in today’s healthcare market. Breakaway offers health strategy and research for the real world. For more information, visit http://www.BreakawayPolicy.com.

Mehlman Vogel Castagnetti is a DC.-based, bipartisan strategic government affairs firm that helps a wide range of entities, including health care providers, physicians, biopharmaceutical companies, and health plans, achieve their objectives in the nation’s capital.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to the life sciences industry. inVentiv offers convergent services that accelerate the performance of companies working to improve human life. In 40 countries around the world, inVentiv’s 12,000 employees work with more than 550 pharmaceutical, biotech and device companies, as well as companies that see health as a central part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health helps clients transform promising ideas into commercial reality. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Health Appoints Andrew J. Suchoff Chief Human Resources Officer Overseeing a Global Workforce of 12,000

BURLINGTON, Mass. (September 10, 2013) – inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, announced today the appointment of Andrew J. Suchoff as Chief Human Resources Officer to oversee a workforce of 12,000 people in more than 40 countries around the globe.

Suchoff brings nearly 30 years of experience to the job, including about a decade overseas managing talent in London, Singapore and Geneva. He has built HR infrastructure to support rapid global growth, led integrations of key acquisitions, overseen dramatic cultural transformations and designed learning and development organizations recognized for excellence by Training magazine.

As the global HR leader of a high-growth company with 30,000 employees, Suchoff led large teams of HR professionals and managed global recruiting across multiple legal and regulatory environments in 22 countries.

“Andrew brings inVentiv exactly the experience, global perspective and deep skills we need to build a high-value organization known as a great place to work,” said Paul Meister, CEO of inVentiv Health. “His diverse experience working across multiple industries, including life sciences, gives him immediate insight attracting and retaining top talent.”

Suchoff’s experience includes working as a Managing Partner at TAG Global Systems, EVP of Global Human Resources at Stream Global Services, and Chief Human Resources Officer at Insulet Corporation. As the SVP of U.S. Human Resources for Serono International, acquired by Merck KGaA, he played a key role in shifting the company culture toward greater collaboration and significantly improved organizational capability.

A graduate of Northeastern University, Suchoff will report to CEO Paul Meister and serve on the company’s Executive Leadership team. He replaces Duncan Harwood, who is returning to Texas for personal reasons, but who will continue to provide counsel to inVentiv Health.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 12,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inVentivHealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

Chandler Chicco Companies Expands Agency Teams With More Than 20 New Hires, Including New DC Lead

NEW YORK, NY – September 9, 2013 – Global health communications agencies Allidura Consumer, Biosector 2 and Chandler Chicco Agency – all part of Chandler Chicco Companies and inVentiv Health, Inc. – have added 20+ staffers to their teams, including a new head of the DC office, in the last 60 days. The hiring spree comes on the heels of new business wins and an uptick in organic growth across all agencies.

Most recently, Heather Gartman joined Chandler Chicco to lead the organization’s DC operations. Heather has more than twenty years of experience in public relations and marketing communications for healthcare clients including patient advocacy groups, medical societies, trade associations, pharmaceutical companies, device manufacturers, and non-profits. She has broad experience in crisis and issues management, advocacy relations, creation and management of public education campaigns, and pharmaceutical brand and corporate public relations.

“DC is playing a central role in healthcare in this country, making strong leadership of our DC office critical,” said Lisa Stockman, founding member and managing director of Chandler Chicco Companies. “Heather has impressive experience working inside the Beltway for more than two decades in both public and private sectors. We couldn’t be more thrilled to have her on board.”

Heather joins from Ruder Finn where she opened and oversaw the DC office, and focused on new business development and strategic oversight for many of the firm’s healthcare brands. Prior to Ruder Finn, Heather served as managing director and head of healthcare for Zeno Group in DC for seven years. Her other agency experience includes Euro RSCG and Earle Palmer Brown. In the public sector, Heather has consulted for many government agencies including the Food and Drug Administration, Department of Energy, Health and Human Services and the State Department.

“Our entrepreneurial culture still attracts the best and the brightest,” said Stockman. “Clients often praise the breadth and depth of talent across our agencies, and appreciate the above-and-beyond efforts their account teams put forth every day on their behalf.”

Other recent key hires across Chandler Chicco agencies include:

In July, Allidura Consumer announced hiring Tracy Naden as co-managing director of the consumer health communications agency. She joined Allidura from W20 Group, where she worked for seven years, most recently in the role of managing director, consumer, at Twist Mktg.

In addition to Tracy, Sharon Bukspan joins the Allidura team from GENYOUth Foundation, where she was a Research Specialist working within the public health space. She graduated with honors from Johns Hopkins University with a bachelor of arts in public health studies, and has her master’s in health science and a certificate in risk science and public policy from Johns Hopkins Bloomberg School of Public Health.

Priya Namjoshi joins Biosector 2’s New York office from Feinstein Kean Healthcare where she was vice president, managing product lifecycle communications, and advocacy and KOL relations across various therapeutic areas, including anti-infectives, neuropsychiatry, and ophthalmology. Prior to Feinstein Kean, Priya was at Porter Novelli where she worked on media campaigns to generate awareness and combat misconception of ADHD medications. She has a master of science in physical therapy from Bombay University, and a master of arts in public relations from Ball State University.

Biosector 2 New York also adds Kathleen Gallagher who joins from Cohn & Wolfe, where she was an account director on several accounts, including vaccines, consumer health and melanoma. Previously, Kathleen was at Porter Novelli where she worked in therapeutic categories such as Alzheimer’s disease, depression and hemophilia. She graduated magna cum laude from Boston University, where she majored in communications.

Andrea Dagger joins Chandler Chicco Agency (CCA) New York from WCG where she was a director overseeing multiple pharmaceutical accounts. She also held positions at Cohn & Wolfe and ToGo Run. Across her career, Andrea has worked for clients such as Pfizer, Colgate Palmolive, Merck, Bristol-Myers Squibb, Bayer Healthcare, McNeil Consumer Healthcare, Eli Lilly and Company, Jenny Craig and The American Red Cross. She has a bachelor of arts in English literature from Drew University.

Shannon Coughlin joins CCA New York from WCG/Twist Mktg, where she was a senior account manager overseeing strategic account direction for various clients, including market development planning for a high-profile pain franchise, consumer launch of an innovative diabetes device, and data publicity for a liver cancer treatment. Shannon also held positions at Porter Novelli and HealthSTAR Public Relations. She studied psychology at Kansas State University.

CCA New York also adds Lisa Benoit from The Ruth Group where she was an account supervisor on medical devices, diagnostics and life sciences accounts spanning therapeutic categories such as spine, cardiology, breast cancer, sleep apnea, regenerative medicine, and stroke. Previous work included positions at Communication Partners & Associates and Aetna. Lisa graduated magna cum laude from Boston College, where she majored in communication, and minored in French and history.

CCA London adds Sabrina Gomersall, formerly a director at WCG, to the team. She brings more than a decade of experience in integrated global and local communications including ethical, digital and mobile health, devices, diagnostics and consumer health. She has worked across a wide variety of therapeutic areas, including cardiology, oncology, rare diseases, multiple sclerosis, and diabetes. Prior to WCG, Sabrina held positions at OgilvyHealth PR and Ruder Finn. She holds an MSc in chemistry from the University of Bristol.

Carly McLean joins CCA West from Weber Shandwick where she was a group manager and spearheaded communications support for product portfolios that spanned consumer, pharmaceutical and biotech accounts. Prior to Weber Shandwick, Carly worked at MSL New York and Atlanta on various consumer and health accounts. She has a bachelor of arts in communications from the University of Kentucky.

CCA West also adds Nicki Polatin from Chempetitive Group where she was a public relations director responsible for strategic corporate and product communications programs. Prior to Chempetitive, Nicki held positions at the German offices of MSL and Weber Shandwick. She has extensive health experience across therapeutic categories, such as endocrinology, pain, oncology, neurology, and cardiology. A native German, Nicki also speaks Polish, French, and Spanish. Nicki has a bachelor of arts in French from Rhodes College, and a master of science in journalism from Northwestern University.

Marian Cutler joins Chandler Chicco’s corporate practice from Brodeur Partners where she provided counsel informed by a strong understanding of how communication best supports and aligns with business strategies to C-suite and senior management clients. Prior to that, she was a Senior Vice President at Makovsky+Company. Her work spanned all facets of corporate communications, done on behalf of health clients such as Introgen, Organ Recovery Systems, UCB, Dignity Health and NovaSure. She has a bachelor’s degree from State University of New York at Albany.

Julia Clark joins Chandler Chicco’s digital practice from Women About where she worked as Executive Producer. Previously, she worked at Grey Healthcare Group and Greater Than One as Director of Project Management. Julia also held positions at Ogilvy Interactive and R/GA and has managed accounts for clients such as American Express, Bayer, Cisco, DuPont, Genentech, IBM, Johnson & Johnson, Medtronic, Nike, Nestlé, and Thomson Reuters. She has a bachelor of fine arts from New York University.

In addition to the hires noted above, Chandler Chicco Companies added eight account team members and welcomed an incoming class of 11 graduate trainees hailing from prestigious universities like Cornell, Wake Forest, Vanderbilt, University of Michigan, and Georgetown.

About Chandler Chicco Companies
Chandler Chicco Companies (CCC) is a global health communications group made up of agencies that deliver unmatched perspective and creative know-how. With an integrated approach to communications, CCC agencies offer best-in-class capabilities spanning public relations, digital and social media, medical and scientific education, marketing and branding, graphic design and multimedia, and research and measurement.

CCC is part of inVentiv Health, Inc. with companies based in New York, Los Angeles, Washington, London, Paris, Shanghai and Frankfurt, as well as global healthcare network operations in 40 markets. For more information, visit www.chandlerchiccocompanies.com.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 12,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inVentivHealth.com.

inVentiv Health Partner Mytrus Inc. Wins Prestigious Award for its Pioneering Technology in Electronic Informed Consent

Frost & Sullivan Presents Mytrus with 2013 North American Product Leadership Award in Clinical Trials

SAN FRANCISCO, CA – August 26, 2013 – inVentiv Health, offering best-in-class clinical, commercial and consulting services to the biopharmaceutical industry, announced today that partner company Mytrus Inc. won Frost & Sullivan’s prestigious Product Leadership Award for pioneering electronic informed consent for clinical trials.

Informed consent is one of the most important, but neglected, elements of enrolling patients in clinical trials and Mytrus technology is transforming the process.

Frost & Sullivan, a respected global research organization that tracks more than 250,000 companies, compared Mytrus to key competitors in a rigorous review and named Mytrus winner of the North American Product Leadership Award in Clinical Trials.

“Mytrus has developed a simple, yet effective and elegant product that is completely changing the way clinical trials are enrolled and consented,” Frost & Sullivan concluded in their final report. “Electronic informed consents are easy and save time for both the sponsors and participants” in clinical trials.

According to ClinicalTrials.gov, there were more than 60,000 registered clinical trials ongoing in the United States last June. Studies are often long and complex. The time and effort spent recruiting patients can represent a third of the cost of trials, yet once enrolled in a trial, patients often drop out due to poor understanding of the treatment protocol. All of this contributes, in the end, to higher drug development costs.

Earlier this year, inVentiv Health took an equity position in Mytrus as part of a suite of services and technologies inVentiv has assembled to dramatically improve trial efficiency. Shortly afterward, the company launched inVentiv Clinical Trial Recruitment Solutions (iCTRS) to help trial sponsors accelerate recruitment, improve site productivity and reduce study timelines.

iCTRS merges inVentiv’s vast proprietary database, communications expertise rooted in behavioral research and innovative digital technologies and social media to aid clinical trial sponsors under pressure to speed drug development. Mytrus’ technology and methodology revolutionizes the study start-up phase by expediting and improving enrollment.

“Mytrus has developed a product that makes the cumbersome, but critical process of informed consent simple and efficient for participants and offers sponsors and regulators new opportunities to collect and track important informed consent data analytics,” Frost & Sullivan wrote.

Informed consent typically contains 8 to 50 pages of often-complex information. Participants frequently fail to read or understand the documents before they consent to participating in a trial. Further, there are no requirements for assessing participants’ understanding of the protocol or risks.

A study published earlier this year in the Public Library of Science showed that patients and investigators receiving information electronically via Mytrus on iPads had far greater comprehension and retention of the material than those receiving the same information on paper.

“We are humbled to receive this award for our work in the area of eConsent and we are encouraged to see the number of companies rushing to adopt more patient-centered tools for clinical research,” Mytrus CEO Anthony Costello said.

Mytrus will accept its award at a gala dinner sponsored by Frost & Sullivan in San Jose, CA. on September 9th.

About inVentiv Health Clinical
inVentiv Health Clinical, formerly PharmaNet/i3, is a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, offering therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical services, and strategic resourcing from a single clinical professional to an entire functional team. With 7,000 passionate employees in more than 36 countries, inVentiv Health Clinical works to accelerate high quality drug development programs of all sizes around the world. http://www.inVentivHealthClinical.com.

About Mytrus
Founded in 2009, Mytrus is a California-based clinical technology and services company built on the idea that modern technologies can enable people to safely and effectively participate in clinical trials without requiring them to live near a study center. The company’s proprietary methods can dramatically improve patient recruitment timelines, increase patient retention and reduce overall study costs for sponsors. Learn more about Mytrus at www.mytrus.com or find the company on Facebook and Twitter @mytrus.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inVentivHealth.com.

ParagonRx, An inVentiv Health Company, Names Former U.S. Food and Drug Administration Official to Position of Chief Medical Officer

Dr. Stephen W. Sun to Support Clients with Regulatory and Strategic Insights on the Optimal and Safe Use of New Drugs and Devices

BURLINGTON, Mass. – August 19, 2013 – ParagonRx, an inVentiv Health company offering product safety risk management and healthcare systems consulting to pharmaceutical and medical device companies, announced today the appointment of Stephen W. Sun, MD, MPH, as Chief Medical Officer advising clients on regulatory and safety issues.

Dr. Sun, formerly with the U.S. Food and Drug Administration (FDA), will be reporting directly to ParagonRx President Jeffrey Fetterman.

His appointment comes at a time of dramatic regulatory change in both the United States and globally. Regulators are under pressure to speed review of new medical products while simultaneously improving safety. As a consequence, drug developers and device makers planning for a successful review must be proactive in assuring optimal and safe use of products before the products come up for review.

“The focus today is on enhanced pharmacovigilance, putting preventions in place before any regulatory body requires it,” Fetterman said. “Dr. Sun’s FDA experience will enrich the guidance we offer clients to assure that active risk management is at the core of developing all new products and services.”

ParagonRx clients will have access to a savvy regulatory strategist in Dr. Sun, who understands the escalating scientific rigor regulators expect to see in filings. His public health experience also will benefit clients seeking counsel on the appropriate use of medications and devices designed to improve the well-being of large populations.

Dr. Sun earned his Bachelors of Science in Chemistry, Food, and Nutrition from Rutgers University, his medical degree from UMDNJ-New Jersey Medical School, and his Masters in Public Health from the Johns Hopkins Bloomberg School of Public Health.

While training in general surgery at Beth Israel Medical Center in New York City, he dedicated his off-hours to developing a medical internet start-up. He eventually left residency to work full-time on his medical knowledge company, Medtower, which delivered relevant late-breaking news to research scientists in the life sciences.

Dr. Sun then transitioned to work for the pharmaceutical industry, first at Organon in Drug Safety and Medical Knowledge Management. He next joined Alpharma as Director of Drug Safety, managing the team responsible for adverse events, product complaints and medical information for all U.S. generic and branded drugs. He was soon promoted to Senior Director of Medical Affairs, where he oversaw Phase I, II and IV clinical studies, risk management plans, pharmacovigilance, medical education, scientific publications, government affairs, health outcomes, and supported sales and marketing teams as well as working with medical science liaisons.

After King Pharmaceuticals' acquisition of Alpharma, Dr. Sun served as King's Senior Director of Pharmacovigilance and Risk Management before moving on to further expand his industry experience in over-the-counter medications at Reckitt-Benckiser. With an interest in public health, Dr. Sun joined the FDA as a Medical Officer. He has served in the CDER Division of Risk Management and most recently in the Controlled Substances Staff. Highlights of his tenure at the FDA include the TIRF class REMS, the proposed standardization of abuse-related adverse event MedDRA terms and the development of a surveillance system using mobile technology.

“Dr. Sun’s experience and know-how, combined with ParagonRx’s systematic approach to minimizing risks, enable us to define pathways for optimal utilization of products and ease the path for our clients,” Fetterman said.

About ParagonRx
ParagonRx, an inVentiv Health company, is a leading provider of risk and benefit consulting services to the pharmaceutical and medical device industries. The company guides clients through proactive planning across the life cycle of products with REMS, RMPs, and post-marketing commitments. Its benefit-risk management expertise, systematic methodologies, and standardized tools, coupled with the unique suite of services available through our affiliates at inVentiv Health, provide end-to-end support for our clients to improve patient safety and enable commercial success. For more information, visit http://ParagonRx.com.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inVentivHealth.com.

Three Executives from inVentiv Health Clinical and Communications Recognized on Prestigious List of PharmaVoice 100 Industry Leaders

Executives Recognized for Innovation and Excellence in Managed Markets, Consumer Education and Clinical Trial Data Quality

BURLINGTON, Mass. – August 6, 2013 – inVentiv Health, offering best-in-class clinical, commercial and consulting services, today congratulated three executives from its clinical and communications businesses named to the PharmaVoice100 list for their exemplary innovation within the healthcare industry.

John Guarino from Palio+Ignite, Tim McCort from GSW Fueled by Blue Diesel, and Pam Strobel from inVentiv Health Clinical were all recognized on a list that includes “extraordinary leaders, innovators, game changers, researchers and scientists, clinical experts, technologists, patient advocates and mentors.”

“All three of these people are thought leaders, innovators in their fields and reflect the excellence found across the 13,000 people worldwide who work for inVentiv Health,” said inVentiv Health CEO Paul Meister. “We congratulate John, Tim and Pam on this well-deserved industry recognition.”

PharmaVoice calls Guarino, who has more than two decades of industry experience, a managed markets communications “guru.” “In less than three years, he has built a managed markets team at Palio+Ignite Managed Markets that is a force to be reckoned with,” the magazine said. As Executive Vice President Managed Markets and Global Payer Access, Guarino makes sure his team on two coasts is well-tuned on reimbursement, effective pull-through, specialty drugs and specialty pharmacy and contracting profitability. They understand the differences and similarities between traditional marketing and payer marketing, which allows them to deliver strategies and tactics that ensure access and reimbursement success critical to the brands they are managing.

Among Guarino’s innovations is the launch of a blog series called Managed Markets Monday focused on sharing insights on comparative effectiveness research, Medicare Part D and the Affordable Care Act. “John knows that marketing strategies must keep pace with how healthcare delivery is changing and that the success of a brand today depends on understanding the managed market environment,” Meister said.

McCort was recognized by PharmaVoice as a master storyteller who says he walks into every meeting believing there is a 50% or greater chance that he is wrong - which forces him to listen. Early in his career, McCort built powerhouse campaigns for major consumer brands such as McDonald’s before turning his skills to take on one of the nation’s biggest challenges, helping more people choose to actively improve their health. Today, as Executive Vice President and General Manager of GSW, he is a key leader of the agency’s diabetes practice and says that in health, it is not enough for marketing to sell products, marketing must also help people be successful in changing their own lives. The biggest competitors for healthcare brands aren’t other brands. The real competitors are lack of knowledge, lack of motivation, inaction and the frailties of being human. “Tim has delved deeply into the emerging science of behavior change to inform the very human approach he takes to solving client communications challenges,” Meister said. “It is not surprising that he has become the go-to person for clients seeking the best consumer campaigns in the business.”

As Executive Director of Strategic Resourcing Quality at inVentiv Clinical, Strobel creates initiatives to build process improvements around the quality of clinical trial data in real time. Strobel introduced a centralized remote data review team to improve the efficiency and compliance of monitoring patient visit data for a large pharmaceutical client. Through this, her team was able to quickly identify and resolve quality and safety issues, as well as protocol deviations. Among her other accomplishments is the creation of a quality dashboard tracking system that tracks client audits/assessments, protocol deviations, issue escalation, training compliance and regulatory inspections for each of FSPs in real time. The dashboard allows her to see trends across a single client, as well as all clients, where she can recommend process improvements.

“Faced with increasing pressure to minimize waste and reduce development costs, pharmaceutical clients will be looking for an improved risk-management approach that relies on proactive quality measures,” Meister said. “Pam is an innovator in quality, well ahead of the curve and proactive in a field that is, by nature, retrospective,” Meister said.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inVentivHealth.com.

inVentiv Health Clinical Expands and Strengthens Executive Team with Three Strategic Appointments

Expanded Leadership Team Will Help Oversee Significant New Business Wins

Princeton, NJ. – August 5, 2013 – inVentiv Health Clinical, a leading global supplier of drug development services, today announced the appointment of a President of Phase II-IV Development, Chief Medical Officer, and Chief Financial Officer to strengthen the leadership team overseeing significant business growth.

The expansion of the Executive Leadership Team represents an important investment in the future inVentiv Health Clinical, already considered a Top 5 Global CRO. Dawn Anderson joins inVentiv Clinical as President, Phase II-IV Development, Martin Birkhofer, M.D. assumes the newly created position of Chief Medical Officer, and Richard Shimota becomes Chief Financial Officer.

The addition of the senior talent was fueled by significant new wins in all areas of the clinical business, including Early Stage, Phase II-IV and Strategic Resourcing.

"With the addition of three such seasoned executives, we are strengthening our leadership team with a Medical Officer steeped in industry knowledge, a skilled CFO with a background in project-based businesses, and a strong leader for Phase II-IV who has deep clinical development experience," said Raymond Hill, President of inVentiv Health Clinical. "I am confident that they will help guide our organization along the successful path we’ve followed since the start of the year through to our next stage of growth."

Anderson, Birkhofer, and Shimota will serve on the Executive Leadership Team, reporting to Hill.

Dawn Anderson, President Phase II-IV
Anderson joins inVentiv Health Clinical with broad experience in clinical and drug development and extensive operational expertise. With more than 20 years in the clinical field across various management positions, she most recently served as Cognizant’s Global Head of Clinical Operations and Transformation. While there, she built the business from start to a thriving global organization. Her experience includes leadership roles across clinical development and operations, portfolio and program management, and process optimization at pharmaceutical and biotech companies, start-ups and CROs. Prior to Cognizant, Anderson held a number of senior roles at Quintiles, including VP of Global Clinical Operations, and VP of Internal Medicine.

Martin Birkhofer, M.D., Chief Medical Officer
In the newly created role, Dr. Birkhofer, a medical oncologist by training, will oversee strategic investment in areas that expand upon inVentiv Health Clinical’s world-class capabilities. He will advise the business on industry trends and issues and build relationships Chief Medical Officers and senior executives within client organizations.

A 19-year veteran of Bristol-Myers Squibb, Dr. Birkhofer most recently served as Vice President, Business Development, leading global search, evaluation, and diligence for worldwide business development. Dr. Birkhofer previously managed Global Medical Affairs for oncology. He led the development team responsible for the U.S. registration, launch and life cycle management of Erbitux® in colorectal cancer, as well as head and neck tumors. Earlier in his career, he was responsible for the BMS Oncology Clinical Research team in Europe and the Clinical Pharmacology team supporting the oncology, immunology and anti-infective pipeline.

Richard Shimota, Chief Financial Officer
Shimota’s unique combination of financial acumen and deep experience in project management for the engineering and construction sector business will be invaluable to inVentiv Health Clinical which also works on a project basis.

Shimota brings nearly 30 years of professional experience in operational finance roles of increasing responsibility to inVentiv Health Clinical. Most recently, he served as CFO of Shaw Power, a division of The Shaw Group, Inc.

About inVentiv Health Clinical
inVentiv Health Clinical is a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, offering therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical services, and strategic resourcing from a single clinical professional to an entire functional team. With 7,000 passionate employees operating in 70 countries, inVentiv Health Clinical works to accelerate high quality drug development programs of all sizes around the world.
http://www.inVentivHealthClinical.com

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inVentivHealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Health Creates Industry’s Largest Global Network of Medical Communications Experts with Expansion Into Tokyo and New York City

inVentiv Medical Communications Adds Significantly to Its International Team of Scientists, PhDs and Experts Delivering Sophisticated Peer-to-Peer Communications

BURLINGTON, Mass., July 29, 2013 – inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that its medical communications business has opened two new offices in Tokyo and New York creating the industry’s largest global network of experts in peer-to-peer medical and scientific communications.

In opening the two new offices, inVentiv Medical Communications (iMC) dramatically expands its existing team of 180 scientists, writers, communications experts and PhD’s in offices across North America, Europe and Asia. iMC has been expanding its global footprint in response to client demand for its unique expertise, and already has offices in London, Munich, Paris, Shanghai, Dallas and the Philadelphia area.

iMC understands healthcare professionals and health systems throughout the world, so can offer clients both a global perspective and local insights. The result is rich, persuasive communications that educate and influence the clinical and payer audiences the healthcare industry must reach for successful commercialization.

iMC is uniquely focused on facilitating peer-to-peer and scientific communications. Its use of a full range of communications channels is bolstered by employing cutting-edge digital technology. Working in close partnership with clients, iMC provides medical strategies for Advisory Boards, medical content development and publication, virtual and in-person events and communications between physicians, nurses and healthcare professionals. The goal is to build relationships, foster understanding and encourage collaboration between the biopharmaceutical industry and medical/healthcare professionals.

“inVentiv Medical Communications bridges the gap between clinical trials and the commercialization of a product,” said Paul Meister, CEO of inVentiv Health. “This type of sophisticated support has never been more important in facilitating access to products because market access today is about more than just the cost of a drug.

“Access means ensuring that clinicians prescribing a drug or using a device have the data they need, are up-to-date regarding the disease or condition being treated, know why a product works and understand how to derive maximum benefit for patients. That’s why more and more clients are turning to the experts at iMC for support.”

Nearly all iMC personnel hold PhD’s or other advanced degrees. The team includes oncologists, hematologists, neuroscientists, biologists, pharmacists, medical writers, program managers, strategists and specialists in market access.

“With this level of expertise, we are able to help clients influence change within clinical and payer audiences,” said Elaine Ferguson, Global Managing Director of iMC. “Now, with these new offices, we are everywhere our clients need us to be, providing scientific rigor and value- based communications solutions that are the best in the business.”

The new staff members in New York City were formerly part of Noveida Health. John LaPolla, who will lead the New York team, holds degrees in microbiology from Cornell University and in biochemistry from Mount Sinai Medical Center. For 14 years, he has specialized in oncology and chronic pain, as well as cardiometabolic and psychiatric disorders. He has been an innovator in market access and has developed cutting-edge technology platforms for some of the world’s largest pharmaceutical companies, as well as for biotech startups.

In Tokyo, iMC will be led by Aya Tokaji as Director of Scientific Services. The Tokyo team will work alongside iMC’s China office which earlier this month won a contract to provide a global pharmaceutical client with assistance in understanding China’s oncology landscape and support at an upcoming medical meeting on oncology.

iMC has the unique ability to tap into and integrate an extensive range of creative capabilities across all of inVentiv Health, including public relations, advertising and marketing, as well as clinical trial, outsourced sales, risk mitigation, compliance and broad patient support expertise.

“At inVentiv, medical communications isn’t an afterthought as it is at other communications firms. Rather, it is absolutely integral, a core capability and built into everything we do,” Ferguson said. “For companies wanting to accelerate time to market, the sophisticated medical communications we can provide has become mission critical.”

About inVentiv Health Communications
inVentiv Health Communications (iHC) is the inVentiv Health division dedicated to delivering exceptional, global, multichannel communications to organizations focused on health and wellness. The company’s unified offer brings together inVentiv Health’s advertising, public relations, public policy, market access, medical communications, media, creative, branding and digital services creating a “Super Agency” structure. iHC provides relevant, targeted and flexible marketing solutions for the pharmaceutical industry and organizations with a healthcare focus, enabling clients to excel in a rapidly changing environment.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inVentivHealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Health Launches Unique Solution to Help Clinical Trial Sponsors Over the Hurdle of Recruitment and Retention

inVentiv Clinical Trial Recruitment Solutions Applies Advanced Technology and Insights from Behavioral Research to Recruit Patients and Physicians and Speed Drugs to Market

BURLINGTON, Mass., June 24, 2013 – inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services, today launched inVentiv Clinical Trial Recruitment Solutions (iCTRS) to solve the costly problem of identifying, recruiting and retaining patients and trial investigators.

Patient recruitment is one of the biggest obstacles in clinical research, and a major cause of delays in developing promising new treatments. The Tufts Center for the Study of Drug Development found enrollment rates over 13 years have dropped 20%. Nearly half of physician sites fail to meet their enrollment targets, and more than 10% of sites never enroll a single patient. Clinical trial patient drop-out rates stand now at 52%.

Nearly 30% of the time spent in clinical trials is dedicated to patient recruitment and enrollment, making it the most time intensive of all tasks. A typical Phase III trial averaging three years requires nine months for recruitment. The costs are huge. The recruitment bottleneck is impacting scientific progress and slowing the performance of companies that patients count on to deliver the next generation of medicines.

iCTRS was created to remove the bottlenecks in ways that have never been done before. The new service helps trial sponsors accelerate recruitment, improve site productivity and reduce study timelines. It merges inVentiv’s vast proprietary database, communications expertise rooted in behavioral research and innovative digital technologies and social media to aid clinical trial sponsors under pressure to speed drug development.

“The magnitude of the challenge prompted us to identify the resources within our organization that could help solve a problem that all sponsors face,” said Paul Meister, Chief Executive Officer of inVentiv Health. “We pulled apart the problem, focused our diverse capabilities on solving each part and the result is a major step forward in recruitment and retention.

“We believe we will be able to significantly reduce the cost of trials, as well as improve time to market.”

Although begun only three months ago, iCTRS already has contracts with three pharmaceutical and biotech companies to do planning and recruitment for four clinical trials.

CAPABILITIES AND RESOURCES

As part of inVentiv Health, iCTRS has the most comprehensive array of data assets and analytics capabilities in the industry. iCTRS uses technology to aggregate data from which algorithms quickly identify the highest-performing investigators around the world – a huge advance over the current state of manually aggregating data.

The algorithms use data from a rich variety of sources such as integrated claims information from more than 900,000 physicians and 115,000 investigators. It also uses current, longitudinal prescription information from more than 100 million U.S. patients. The same expertise and technology underpin enrollment modeling and risk management. iCTRS technology enables a detailed and real-time view of recruitment, enrollment and retention – actionable information for sponsors and sites.

Finally, no other company has such deep communications expertise applied to patient recruitment. Recruitment strategies are rooted in behavioral research conducted by inVentiv scientists and communications expertise from experts in healthcare communications. Understanding the patient journey is key to retention, commercialization and adherence.

PARTNERSHIPS

To enhance its offerings, iCTRS has formed partnerships that enhance its ability to effectively reach physicians and patients and expedite enrollment. Among the recent partners are Medikly, PatientsLikeMe and Mytrus.

Medikly’s multichannel digital technology helps pharmaceutical companies identify, engage, and retain clinical trial investigators by applying a real-time view of doctors based on their preferences and behaviors online. Pharmaceutical companies gain a rich, multidimensional understanding of a physician’s specific areas of interest, preferred method of communications, influence within their community, and a great deal more. Such insights help overcome barriers between those wanting to recruit investigators and the physician.

The PatientsLikeMe partnership will help bring more people more quickly into medical research and clinical trials. PatientsLikeMe’s 200,000 members share information and experiences on more than 1,500 different diseases and conditions. Members interested in the development of new treatments can now become even more active in medical research by accessing information on clinical trials conducted by inVentiv’s pharmaceutical customers.

In March, inVentiv Health announced that it had taken an equity stake in Mytrus, Inc., a pioneer in “virtual clinical trials” and technologies such as electronic informed consent to improve trial efficiency. Mytrus has been expanding the boundaries of traditional clinical trial research with the first all-electronic, home-based clinical trial to gain U.S. Food and Drug Administration approval and IRB (Institutional Review Boards) approval.

"The launch of inVentiv Clinical Trial Recruitment Solutions is another example of our commitment to creating unique solutions that tap some of the broadest global expertise in the healthcare services industry,” said Jim Carroll, Vice President of Product Management and Marketing. “We have created lean, adaptable services to deliver faster and more predictable outcomes to life science companies that want to accelerate trial completion and position their product for market success.”

To learn more about inVentiv Clinical Trial Recruitment Solutions, contact jim.carroll@inventivhealth.com or 781-425-6645. Additional information is also available at www.inventivhealth-ictrs.com.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

PatientsLikeMe and inVentiv Health Partner to Accelerate Clinical Trial Research

First Agreement Between the Online Patient Network and Global Clinical Research Organization Promises to Help Speed Recruitment for Drug Development

BURLINGTON, Mass., June 17, 2013 – inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services, today announced a partnership with the innovative online patient network PatientsLikeMe to bring more people more quickly into medical research and clinical trials.

This is the first such agreement between the global patient recruitment organization for inVentiv Health Clinical and PatientsLikeMe, whose 200,000 members share information and experiences on more than 1,500 different diseases and conditions. PatientsLikeMe members, already interested in the development of new treatments, can now become even more active in medical research by accessing information on clinical trials conducted by inVentiv’s pharmaceutical customers.

”inVentiv Health will be able to quickly recruit potential trial participants by tapping into one of the fastest growing and most active patient networks online, so that our customers can speed up the development of drugs, devices and treatments to improve patients’ lives,” said Raymond Hill, President of inVentiv Health Clinical.

PatientsLikeMe members share their experiences so that they can learn more about disease, help others, and contribute data to real-time healthcare research.

“We’ve pioneered a way for people to learn from, share and contribute health data, and removed traditional barriers between researchers and patients,” said Michael Evers, Executive Vice President of Marketing and Patient Advocacy at PatientsLikeMe. “inVentiv Health is a critical partner who shares our goal of streamlining research to quickly get better treatments to the people who need them.”

This agreement is inVentiv’s third recent announcement of a novel partnership focused on accelerating clinical trials. In March, the company announced that it had taken an equity stake in Mytrus, which has been expanding the boundaries of traditional clinical trial research with technology that allows trial sponsors to use electronic informed consent, a significant improvement in efficiency and speed. Last week, the company announced a partnership with Medikly to gather data, enabling the faster recruitment of clinical trial investigators.

About PatientsLikeMe
PatientsLikeMe is a patient network that improves lives and a real-time research platform that advances medicine. Through the network, patients connect with others who have the same disease or condition and track and share their own experiences. In the process, they generate data about the real-world nature of disease that help researchers, pharmaceutical companies, regulators, providers and nonprofits develop more effective products, services and care. PatientsLikeMe is a trusted source for real-world disease information and a clinically robust resource that has published more than 30 peer-reviewed research studies. Visit us at www.patientslikeme.com or follow us on our blog, on Twitter or via Facebook.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Health Partners with Medikly to Speed Clinical Trials by Accelerating the Recruitment of Investigators

Medikly’s Sophisticated Technology Helps to More Effectively Identify and Engage Investigators

Burlington, Mass. – June 11, 2013 – inVentiv Health Inc., offering best-in-class clinical, commercial and consulting services, announced today a strategic partnership with Medikly, Inc., an innovative provider of physician engagement solutions, as part of ongoing efforts to help pharmaceutical companies develop better drugs faster and more cost effectively – and get them to market more quickly.

Medikly’s multichannel digital technology helps pharmaceutical companies identify, engage, and retain clinical trial investigators by applying a real-time view of doctors based on their preferences and behaviors online. Pharmaceutical companies gain a rich, multidimensional understanding of a physician’s specific areas of interest, preferred method of communications, influence within their community, and a great deal more. Such insights help overcome barriers between those wanting to recruit investigators and the physician.

Medikly allows trial sponsors to discover physicians likely to be interested in becoming trial investigators because of their work and characteristics that predispose them to research or to recommend patients for a trial. The technology enables trial sponsors to create communities for investigators, develop relevant and sophisticated medical education programs, then measure and apply engagement metrics to understand how healthcare providers will respond to messages. It also allows a pharmaceutical company to expand trial awareness, build trust with physicians, accelerate acquisition rates, and improve relationships.

“By now, we all know that digital technologies can streamline clinical trials and save costs, but the challenge is knowing which technologies to use and how to best deploy them to save the most money and time,” said Raymond Hill, Executive VP of Clinical for inVentiv Health. “This takes a special kind of expertise, grounded in broad global experience and deep insights into every aspect of drug development. inVentiv Health has that expertise and it is what drives our investment in technologies like Medikly to accelerate clinical trial success.”

While Medikly is primarily focused on the marketing of pharmaceutical products, this agreement gives inVentiv Health exclusive access to their platform and data-collection tools to use in clinical trial recruitment.

“With the Medikly platform, inVentiv will be able to help pharmaceutical clients capture and translate multichannel data into insights and interactive experiences that reach and engage physicians,” said Venkat Gullapalli, MD, CEO and Founder of Medikly. “inVentiv Health has had the foresight to leverage the right digital tools to position itself – and its customers – ahead of the curve.”

Hill noted that inVentiv has 13,000 employees working collaboratively across the globe in diverse healthcare services, as well as a network of a half million healthcare providers, that together give the company the ability to forecast industry trends and opportunities. This allows the company to identify and integrate technologies that solve both current and future problems in ways that no one else can.

“Our approach to streamlining clinical trial recruitment of both physicians and patients is strategic, effective, cost efficient and fast,” Hill said. “This is the future of clinical trial recruitment.”

In May, the respected analyst firm Gartner Inc., identified Medlikly’s platform as a “disruptive technology” and game-changing innovation for pharmaceutical organizations seeking “actionable insights” from detailed practitioner profiling across all available channels (social, face-to-face, mobile, digital, and web). The data facilitates personalized messaging and optimized sales efforts around the individual physician reduce wasted … effort.”

Earlier this year, inVentiv Health announced a strategic investment in Mytrus, which has launched the first FDA-approved electronic informed consent technology in the marketplace. Additional partnership announcements are planned for the coming weeks.

About Medikly
Medikly is pharma’s first and only unified, cloud-based platform that helps brands, better reach, engage, and understand physicians on an individual level. Medikly’s platform goes beyond current technology solutions by delivering deeper content, interactive experiences, while providing a robust set of measurable and actionable big data analytics. For more information, visit www.medikly.com or email info@medikly.com.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Health Names Sydney Rubin as Chief Communications Officer

Rubin to Oversee inVentiv’s Growing Reputation as a Sophisticated Global Provider of Clinical, Commercial and Consulting Services to a Healthcare Industry in Transition

Burlington, Mass. – May 21, 2013 – inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, announced today the appointment of Sydney Rubin as Chief Communications Officer. Rubin, who will report to inVentiv Health CEO Paul Meister, will oversee corporate reputation, internal communications, media relations and public affairs.

Her appointment reflects need to build and manage inVentiv’s worldwide reputation in the context of significant growth and expansion over the last two years.

“Sydney brings decades of communications experience to inVentiv Health, and a clear understanding of the role that consistent, integrated and compelling communications plays in building a high-value organization with a world-class reputation,” Meister said. “She will help raise awareness of inVentiv and our unique combination of sophisticated services for clients in the life sciences industry.”

Bob Chandler, Senior Vice President of Marketing and Communications, will work alongside Rubin providing strategic counsel and marketing expertise.

Rubin has managed public relations programs for a broad range of corporate and institutional clients in the pharmaceutical and healthcare, consumer products, technology and financial services sectors. She has developed and implemented global communications strategies for both early-stage businesses and some of the best known brands in the world.

She moves up to inVentiv Health’s corporate team from Chandler Chicco Companies, part of inVentiv Health Inc., where she provided senior counsel in corporate reputation, content development, crisis communications, executive training and public affairs. She joined Chandler Chicco with the purchase in 2005 of the Washington, D.C. public relations and public affairs firm she founded, Ignition Strategic Communications. Prior to Ignition, Rubin spent nearly a decade as a foreign correspondent with The Associated Press and is the winner of numerous awards for both her work in public relations and journalism.

“This is a challenging position at a unique company that offers the most sophisticated mix of clinical, commercial and consulting services in the healthcare industry,” Rubin said. “Our approach to combining our global expertise is strategic, effective, cost efficient and fast. In other words, it’s the future of healthcare.”

inVentiv also announced the hiring of Danielle DeForge as Director of Corporate Communications. Danielle’s communications experience, forged at Chandler Chicco Companies, spans the health and wellness spectrum. She has developed award-winning global media relations, public affairs and social media campaigns, and spent the early years of her career overseeing communications programs for consumer, technology and financial services clients at Ignition Strategic Communications.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

inVentiv Health Clinical Named a “Top CRO” From Among 2,000 Investigative Sites Surveyed by CenterWatch

Award is Second This Year to Recognize Excellence of InVentiv Health Clinical

Burlington, Mass. – May 15, 2013 – inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that inVentiv Health Clinical had been rated a Top CRO in a bi-annual survey by CenterWatch, a leading provider of global clinical trial information.

This is the second time this year inVentiv Health Clinical has received prestigious industry recognition. Earlier this year, Pharma Times named the inVentiv Health Clinical as “Clinical Company of the Year.” The CenterWatch 2013 Global Investigative Site Relationship Survey asked investigative sites to rate their clinical trial relationships with CROs. More than 2,000 investigative sites ranked CROs across 36 different relationship attributes and rankings were then based on the number of “excellent” scores each CRO received. inVentiv Clinical rated among the top three CROs.

“To ensure the successful implementation of our clinical trials, we place a very high importance on developing strong collaborative relationships with our investigative site partners,” said Ray Hill, President of inVentiv Health Clinical. “It is gratifying to see these efforts recognized by the investigative sites themselves.”

The full report is available in the May issue of The CenterWatch Monthly Newsletter.

As part of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services, inVentiv Health Clinical is uniquely positioned to offer healthcare companies worldwide services in Early Stage (Phase I), Phase II-III, Late Stage (Phase IV) clinical development and clinical staffing. With 7,000 employees in more than 70 countries, inVentiv Health Clinical’s services can be deployed on any scale from highly complex multinational clinical trials to earlier stage studies involving specialized patient populations to Late Stage post-approval studies, or from placing a single individual at a company to outsourcing a full clinical department. With such broad capabilities, global reach and focus on strong relationships, the company has developed a growing reputation as one of the world’s leading CROs.

CenterWatch is a leading source of clinical trials information for both clinical research professionals and patients. The consulting services and news company is recognized by many of the top media outlets and publications around the world as a leading authority and source of information on the clinical trials industry.

About inVentiv Health Clinical
inVentiv Health Clinical, formerly PharmaNet/i3, is a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, offering therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical services, and strategic resourcing from a single clinical professional to an entire functional team. With 7,000 employees operating in more than 70 countries, inVentiv Health Clinical works to accelerate high quality drug development programs of all sizes around the world. http://www.inventivhealthclinical.com

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

Healthcare Businesswomen’s Association Recognizes Four Talented “Rising Stars” Within inVentiv Health

Burlington, Mass. – May 9, 2013 – inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that four talented women executives have been selected as 2013 “Rising Stars” by the Healthcare Businesswomen’s Association (HBA).

The inVentiv Health honorees included Sabine Dettwiler of Campbell Alliance, Jeanine O’Kane of Chandler Chicco Companies, Jennifer Oleski of GSW Worldwide, and Krystina Smith of Palio+Ignite.

The combined experience of inVentiv’s four Rising Stars spans several decades and a variety of healthcare-specific disciplines including advertising, public relations and consulting:

  • Sabine Dettwiler, Director of the Commercial Center of Excellence in Campbell Alliance’s London office, spearheads strategy development and implementation support across multiple therapeutic areas and geographies.
  • Jeanine O’Kane, Managing Director of Biosector 2, a Chandler Chicco company, has more than 20 years of business leadership experience in the development and execution of global public relations programs.
  • Jennifer Oleski, Vice President at GSW Worldwide, has more than a decade of pharmaceutical advertising experience, including franchise branding, direct-to-patient marketing and professional education promotions.
  • Krystina Smith, Senior Research Analyst at Palio+Ignite, excels in market research, analytics, brand strategy, budget impact modeling and social listening.

Each year HBA recognizes women in the healthcare industry who exhibit visionary leadership skills, are solely dedicated to the healthcare industry, and who contribute significantly to their organizations. To qualify as Rising Stars, honorees must also promote growth opportunities for others and serve as role models within their respective companies.

“These Rising Stars represent the best minds in healthcare. They bring a unique perspective, but also a multidisciplinary approach to an industry in dramatic transition,” said Paul Meister, Chief Executive Officer of inVentiv Health. “Their passion for healthcare and commitment to client service provides inspiration for all of us at inVentiv and we are proud to call them our colleagues.”

The 2013 honorees were recognized at the 24th annual HBA Woman of the Year award luncheon, held May 9, in New York City.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

inVentiv Health Forms Strategic Alliance with Bell Medical Solutions, One of Japan’s Top Clinical Research Organizations

Alliance Expands Bell’s Global Reach While Increasing inVentiv’s Clinical Capabilities in the Growing Japanese Market

Burlington, Mass. – April 11, 2013 – inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, announced today a strategic alliance with Bell Medical Solutions, one of Japan’s top clinical research organizations with more than 700 clinical research associates serving the growing Japanese market.

Bell, a preferred service provider to some of Japan’s top pharmaceutical companies, offers CRO services that cover Phases I-IV, post-approval studies and patient access. Together, inVentiv and Bell will offer comprehensive global drug development services to Japanese and international clients conducting studies in Japan.

“This alliance provides Bell Medical Solutions with inVentiv’s significant international reach and the ability to participate in larger, global studies,” said inVentiv Health CEO Paul Meister. “For inVentiv, the alliance bolsters our already significant position in Japan to better support our clients who are capitalizing on exciting opportunities for growth.”

Speaking recently to The Economist magazine, the Pharmaceutical Research and Manufacturers of America, the pharmaceutical industry trade group, said Japan may be one of the world’s best markets right now for foreign drug companies. Sales growth in 2011 for the top eight multinational drug firms in Japan ranged from 12% to 31%. PhRMA called these “emerging market” growth rates. Firms now are sending some of their brightest researchers to Japan.

Meanwhile, the Pharmaceutical and Medical Device Agency (PMDA), which oversees the approval process for Japan’s Health Ministry, has slashed review times over the last five years and increased the number of new drug approvals to serve the needs of a burgeoning population of elderly.

Headquartered in Tokyo, Bell has conducted hundreds of studies in various therapeutic areas since the company began offering CRO services in 1986. It is the only full-service CRO in Japan and is known for upholding the highest quality and regulatory standards.

“Bell is not just a respected CRO, it is also embedded in the Japanese healthcare and drug approval system,” said Ray Hill, President of inVentiv Health Clinical. “It is a crucial time for our clients operating in Japan and we can now provide all the support they need to succeed.”

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Health Clinical Acquires Equity Stake in Mytrus

Pioneering technologies and global clinical trial expertise converge to offer improved trial execution, faster time to market and reduced product development costs

Burlington, Mass. – March 13, 2013 – inVentiv Health, Inc., offering best-in-class clinical, commercial, and consulting services to the healthcare industry, today announced that it has taken an equity stake in Mytrus, Inc., a pioneer in “virtual clinical trials” and technologies such as electronic informed consent to improve trial efficiency.

Mytrus has been expanding the boundaries of traditional clinical trial research with the first all-electronic, home-based clinical trial to gain U.S. Food and Drug Administration approval and IRB (Institutional Review Boards). inVentiv Health is taking a significant equity stake in Mytrus, as well as establishing a strategic commercial relationship.

“This partnership blends our shared drive for innovation and our complementary experience from the world of high tech and clinical research,” said Paul Meister, Chief Executive Officer of inVentiv Health. “The goal is improved trial execution, accelerated time to market and reduced product development costs for our clients.”

Mytrus technology allows sponsors to use electronic informed consent, a significant improvement in efficiency and speed. It allows a wider range of people to participate in clinical research by removing location as an obstacle to recruitment and bringing trials directly to participants in their homes. Taken together, Mytrus technology enables more cost-effective clinical studies that start and finish faster. At a time when bringing a drug to market can cost up to $1 billion, Mytrus provides solutions for pharmaceutical and device makers eager to find more cost effective ways to conduct research.

“We estimate that up to 30% of studies run today could be done direct-to-patient and 100% of studies and study patients could benefit from electronic informed consent,” said Anthony Costello Co-founder and CEO of Mytrus. “inVentiv Health has the global footprint and clinical research expertise to help us bring the benefits of our technology more quickly to trial sponsors and patients worldwide.”

Patients who match the eligibility criteria for a study can live anywhere and submit their data remotely, allowing sponsors to conduct more cost-effective recruitment campaigns and making participation more convenient for patients and physician-investigators. Sponsors are able to reduce the number of study sites required to run a clinical trial by as much as 80 percent, which dramatically increases savings in time and costs throughout the trial, especially during the study start up phase.

“Reducing the overall cost of clinical trials and increasing patient recruitment remain serious issues for sponsors,” said Ray Hill, President of inVentiv Health Clinical. “Our partnership with Mytrus will allow us to recruit and retain a broader base of patients more quickly to help meet our clients’ needs.”

About inVentiv Health Clinical
inVentiv Health Clinical, formerly PharmaNet/i3, is a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, offering therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical services, and strategic resourcing from a single clinical professional to an entire functional team. With 7,000 passionate employees in more than 36 countries, inVentiv Health Clinical works to accelerate high quality drug development programs of all sizes around the world. http://www.inventivhealthclinical.com

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

About Mytrus
Founded in 2009, Mytrus is a California-based clinical technology and services company built on the idea that modern technologies can enable people to safely and effectively participate in clinical trials without requiring them to live near a study center. The company’s proprietary methods can dramatically improve patient recruitment timelines, increase patient retention and reduce overall study costs for sponsors. Learn more about Mytrus at www.mytrus.com or find the company on Facebook and Twitter @mytrus.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced and future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Health Bolsters Global Communications Leadership Team

Michel Dubery Appointed Managing Director of inVentiv Health Communications/Europe

Burlington, Mass. ‒ February 13, 2013 – inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that Michel Dubery will lead the European arm of the company’s global communications division. Ranked by Advertising Age as the world’s second largest healthcare agency network, inVentiv Health Communications (iHC) employs 1,800 professionals across the globe.

Dubery brings more than 30 years of broad, global healthcare industry experience to iHC, including specialized expertise in consumer and patient communication, relationship marketing, brand strategy development and business modeling. As Managing Director of inVentiv Health Communications/Europe (iHCE), he will oversee the agency’s advertising and public relations offerings.

“iHCE’s goal is to form strategic partnerships with clients that provide them with the necessary support to quickly maneuver in a complex world,” said Bob Chandler, President, inVentiv Health Communications and Senior Vice President, Marketing and Communications, inVentiv Health. “Mounting pressures to limit healthcare costs across Europe are creating new communication challenges for our clients. Michel’s vast knowledge of the market on a regional and global level will enhance our ability to help clients navigate this complicated landscape and reach patients and healthcare professionals in meaningful ways. We are delighted that he is joining us.”

With operational headquarters in London that serves as a hub for all European offices, iHCE designs relevant, targeted and flexible marketing solutions for the pharmaceutical industry and organizations with a healthcare focus, helping clients excel in a challenging and rapidly changing environment. As part of iHC, iHCE operates under a “Done as One” business model that enables the convergence of inVentiv’s best-in-class advertising, public relations, public policy, market access, medical communications, media, creative, branding and digital services. The model allows clients to bring their challenges to iHCE, which then assembles the cross-disciplinary expertise, services and team needed to deliver successful solutions.

Prior to joining iHCE, Dubery served as Managing Director, Europe at Grey Healthcare Group. Under his leadership, the company’s European business margins improved considerably, with the London office experiencing five-fold growth in less than four years. From 2007 to 2009, Dubery served as Chief Strategy Officer, Europe at DDB Health Group, where he redeveloped the agency’s strategic offerings, including new tools and workshops. In addition to his role as Senior Planning Partner at WWAV Rapp Collins, Dubery has held several marketing positions at leading healthcare companies, including Novartis, Sandoz, Hoechst-Roussel and Astra Pharmaceuticals. Earlier in his career, Dubery was a staff nurse specializing in orthopedics at Burnley General Hospital in Lancashire, England.

About inVentiv Health Communications/Europe
inVentiv Health Communications/Europe (iHCE) is the European arm of inVentiv Health Communications, the inVentiv Health division dedicated to delivering exceptional global, multichannel communications for organizations focused on health and wellness. iHCE provides relevant, targeted and flexible marketing solutions for the pharmaceutical industry and organizations with a healthcare focus, enabling clients to excel in a rapidly changing environment. The company’s unified offer brings together inVentiv Health’s advertising, public relations, public policy, market access, medical education, marketing, digital and branding services. iHCE is based in Switzerland with operational headquarters in London.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced and future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Health Clinical Recognized as “Clinical Company of the Year”

Employee Wins “Clinical Trial Administrator of the Year” Award

Burlington, Mass. – February 5, 2013 – inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that, at a ceremony in London, inVentiv Health Clinical was named “Clinical Company of the Year” by PharmaTimes.

“This award recognizes the tremendous value that inVentiv Health Clinical brings to clients,” said Paul Meister, Chief Executive Officer of inVentiv Health. “By linking our Clinical segment with commercial and consulting groups, we are able to offer sophisticated, tailored services that no other CRO can match.”

In addition, inVentiv Health Clinical employee Adi Needham won “Clinical Trial Administrator of the Year.” Needham has been with inVentiv Health Clinical for two years and works as an Unmasked CRA placed at a major pharmaceutical company.

“Our status as a top global provider of CRO services is driven by the quality and dedication of our staff,” said Ray Hill, President of inVentiv Health Clinical. “Both the company and individual awards are a testament of the commitment that we have across the organization to our clients and the patients they serve.”

With 7,000 employees in more than 36 countries, inVentiv Health Clinical is uniquely positioned as a leading clinical research organization to offer healthcare companies worldwide services in Early Stage (Phase I), Phase II-III, Late Stage (Phase IV) clinical development and clinical staffing. These services can be deployed on any scale from highly complex multinational clinical trials to earlier stage studies involving specialized patient populations to Late Stage post-approval studies, or from placing a single individual at a company to outsourcing a full clinical department. About inVentiv Health Clinical

About inVentiv Health Clinical
inVentiv Health Clinical, formerly PharmaNet/i3, is a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, offering therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical services, and strategic resourcing from a single clinical professional to an entire functional team. With 7,000 employees in more than 36 countries, inVentiv Health Clinical works to accelerate high quality drug development programs of all sizes around the world. http://www.inventivhealthclinical.com

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced and future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

PharmaNet/i3 Renamed inVentiv Health Clinical

inVentiv Health More Closely Aligns Clinical Segment to Commercial and Consulting Expertise to Deliver Enhanced, Convergent Clinical Services

Burlington, Mass. – January 30, 2013 –inVentiv Health, Inc., offering best-in-class clinical, commercial, and consulting services to the healthcare industry, today announced that its existing clinical research organization (CRO), PharmaNet/i3, will be renamed inVentiv Health Clinical. This renaming reflects the closer alignment between the Clinical segment and inVentiv’s commercial and consulting services.

“As a top global CRO, renaming ourselves inVentiv Health Clinical demonstrates a company-wide commitment to our clinical clients, who will benefit from seamless, global access to a more robust range of services,” said Paul Meister, Chief Executive Officer at inVentiv Health. “Clients can now access broad inVentiv talent with expertise across the product life cycle to deliver tailored solutions from product development through commercialization.”

Industry veteran Raymond Hill was appointed in December to lead inVentiv Health Clinical. Prior to joining inVentiv, Hill was CEO at Pharmaceutical Product Development, Inc., where he successfully oversaw the process of taking the company private. Before that, Hill was President at IMS Consulting Group, where he oversaw an aggressive strategy of organic and inorganic growth – building the business to $500M in six years. Hill is a graduate of Cornell University and holds a master's degree from Duke University.

“By connecting clinical research and staffing capabilities to consulting and commercial services, inVentiv can offer fully integrated solutions to pharmaceutical, biotechnology, generic drug and medical device companies in a way that cannot be matched by any other CRO in the industry,” said Hill. “One example is our ability to assist clients in Late Stage trials by tapping both digital and adherence experts from other inVentiv companies. Through this approach we can help our clients simplify complex health economics and outcomes research trials.”

inVentiv Health Clinical is a leading clinical research organization offering Early Stage (Phase I), Phase II-III, Late Stage (Phase IV) clinical development and clinical staffing services to healthcare companies worldwide. These services can be deployed on any scale from highly complex multinational clinical trials to earlier stage studies involving specialized patient populations to Late Stage post-approval studies, or from placing a single individual at a company to outsourcing a full clinical department.

“Healthcare companies are continuing to increase their reliance on CROs,” said Hill. “With 7,000 employees in more than 36 countries across the world, inVentiv Health Clinical has the breadth of experience in geographies and the necessary therapeutic expertise to meet the challenges that our clients are facing.”

About inVentiv Health Clinical
inVentiv Health Clinical, formerly PharmaNet/i3, is a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, offering therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical services, and strategic resourcing from a single clinical professional to an entire functional team. With 7,000 passionate employees in more than 36 countries, inVentiv Health Clinical works to accelerate high quality drug development programs of all sizes around the world. http://www.inventivhealthclinical.com

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced and future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Health Launches “Done as One” Integrated Services Model to Better Meet Global Demand for Unified Healthcare Communications Expertise

Model Offers Clients Instant Access to a Whole New Level of Collaboration Among Communications Disciplines Around the World

Burlington, Mass. – January 29, 2013 – inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services, today announced a realignment of its global communications division to better respond to client demand for unified, worldwide communications services. With a network of 1,800 professionals, inVentiv Health Communications (iHC) is ranked by Advertising Age as the world’s second largest healthcare agency network.

iHC will operate under a “Done as One” model that enables the convergence of inVentiv’s advertising, public relations, public policy, market access, medical communications, media, creative, branding and digital services.

“The integration of our communications division is another important step in the evolution of our business strategy designed to deliver all of inVentiv’s capabilities seamlessly to the client,” said Paul Meister, Chief Executive Officer of inVentiv Health, Inc. “In this highly challenging environment, our clients are looking for innovative solutions and this model allows us to more efficiently meet their needs.” Meister added that inVentiv has appointed Bob Chandler to lead the newly realigned division.

Chandler will serve as iHC’s worldwide President while remaining actively involved in the agency he founded, Chandler Chicco Companies. “By connecting these multidisciplinary agencies in what we’re calling a ‘Super Agency’ structure, we offer enormous presence in healthcare and unrivaled perspective on the sector and its future,” said Chandler. “Our goal is to support clients who must quickly maneuver in a complex world where media are ubiquitous, consumers are in the driver’s seat and healthcare is swiftly transforming.”

Joining the newly aligned team is Rob Quish, who serves as iHC’s President of Global Strategy. Quish has played an instrumental role in the agency’s realignment and will focus on enhancing creativity, innovation and collaboration across iHC. He previously held a variety of senior management positions with global advertising agencies, such as J. Walter Thompson Company and Lowe & Partners.

The new convergent services model allows clients to bring their challenge to iHC, which then assembles the cross-disciplinary expertise, services and team needed to succeed. The client-centric team operates with a single point of contact and financial administration. Such seamless, strategic collaboration leads to services that are nimble, flexible and targeted to provide global clients with the support required in a fiercely competitive marketplace.

For the past year, iHC has successfully operated under this model in Europe and China, delivering exceptional, global, multichannel results. In the United States, iHC is composed of a group of well known specialist agencies respected for their high level of expertise.

  • Within the advertising discipline, as part of the U.S. realignment, four agencies are combining to create two digitally driven agencies singularly focused on health engagement. Palio and Ignite Health become Palio+Ignite and GSW Worldwide with Blue Diesel become GSW Worldwide, Fueled by Blue Diesel.
  • Additional expertise to support inVentiv Health Communications agencies comes from three new centers of excellence: inVentiv Creative Studios, providing full-service design, creative and technology capabilities; inVentiv Digital+Innovation, offering global digital strategic solutions, technology platforms and thought leadership; and inVentiv Media 360°, a specialized healthcare media agency providing integrated multichannel communications strategies and media solutions.
  • Existing best-in-class inVentiv Communications’ brands include Addison Whitney, a brand consulting firm; Chandler Chicco Companies, a multiservice global public relations group; The Navicor Group, a full-service marketing communications firm focused on oncology and immunology; Patient Marketing Group, focused on innovative patient relationship marketing programs; and inVentiv Medical Communications, a global network of specialists and agencies delivering full-service medical communications and education.

Clients have the option of accessing individual agency services as before, through their existing agency, or the entire iHC network of seamless services across many more communications disciplines.

By connecting iHC’s multidisciplinary agencies to inVentiv’s clinical and consulting services, iHC can offer deeper strategic solutions across the health and wellness spectrum in a way that cannot be matched by any other agency in the industry.

About inVentiv Health Communications
inVentiv Health Communications (iHC) is the inVentiv Health division dedicated to delivering exceptional, global, multichannel communications to organizations focused on health and wellness. The company’s unified offer brings together inVentiv Health’s advertising, public relations, public policy, market access, medical communications, media, creative, branding and digital services creating a “Super Agency” structure. iHC provides relevant, targeted and flexible marketing solutions for the pharmaceutical industry and organizations with a healthcare focus, enabling clients to excel in a rapidly changing environment.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced and future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

inVentiv Health Strengthens Clinical Leadership Team

Burlington, Mass. – December 10, 2012 - inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced organizational changes within its clinical group. Raymond Hill is joining the Company as Executive Vice President of Clinical, effective December 12, 2012, and will be responsible for leading the Company’s Clinical business segment, which includes Early Stage, Phase II-IV and Strategic Resourcing.

“We are very pleased to welcome a seasoned industry veteran like Ray to inVentiv and expect that his significant experience in both successfully growing pharmaceutical services businesses and leading productive teams will be an asset to our organization,” said Paul Meister, Chief Executive Officer at inVentiv.

Prior to joining inVentiv, Hill was CEO at Pharmaceutical Product Development, Inc., where he successfully oversaw the process of taking the company private. Before that, he was President at IMS Consulting Group, where he oversaw an aggressive strategy of organic and inorganic growth – building the business from $100M in 2004 to $500M in 2010. Prior to IMS, Hill held a series of other positions in pharmaceutical consulting. He earned a Bachelor’s Degree from Cornell University and a Master’s Degree from Duke University.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

PharmaVOICE Names Four inVentiv Health Associates Among “100 Most Inspiring” Leaders in Healthcare

Burlington, Mass. – August 7, 2012 - inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, announced today that leaders from four inVentiv Health companies were included in PharmaVOICE's 2012 list of the "100 Most Inspiring People" in the life sciences industry. inVentiv honorees include Marianne Eisenmann, Kelly Gratz, Leigh Householder and Todd LaRoche.

Every year, the July/August issue of PharmaVOICE features 100 of the “most inspiring individuals” in the life sciences industry as determined by the publication’s readers. Their personal accounts detail how these 100 individuals – executives, peers, colleagues, clients, partners and others – contribute significantly to their organizations, while motivating and mentoring those around them.

“We congratulate Marianne, Kelly, Leigh, and Todd on this prestigious recognition,” said Paul Meister, CEO of inVentiv Health. “All four of them serve as role models to the entire inVentiv organization, inspiring us to question conventional thinking and push the envelope to seek better solutions for our clients. In an industry characterized by increasing complexity and a constant demand for innovation, having strong leaders with a passion for healthcare and a commitment to client service is critical.”

The honorees represent four of inVentiv’s best-in-class businesses. Marianne Eisenmann leads Determinus, the research division of Chandler Chicco Companies. An advocate of communications research, Eisenmann has a proven track record in providing leading global companies with strategic support for public relations program planning and measurement.

Kelly Gratz is President of inVentiv Health Commercial Solutions, which drives the development of unique global commercial solutions for inVentiv’s clients that cross traditional functional boundaries. Since joining the company in 2000, she has held senior leadership roles in inVentiv’s Commercial and Communications divisions, and has been directly involved in leading the delivery of integrated solutions and multi-channel success for a number of top pharmaceutical companies.

Leigh Householder, Vice President/Managing Director of iQ, the innovation lab of GSW Worldwide, has more than 13 years of experience creating digital strategies for Fortune 1000 companies and developing social media approaches in highly-regulated industries. At GSW, she leverages that experience to develop clear points of view on how technology can change healthcare marketing.

Todd LaRoche is Executive Vice President/Managing Director of Creative at Palio. With more than 30 years of advertising and marketing communications experience, he directs creative execution from concept development through final production in all media for both professional and patient audiences.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv’s client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

inVentiv Health Announces Acquisition of Kazaam Interactive

Burlington, Mass. – June 5, 2012 – inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that it has acquired Kazaam Interactive, a full-service interactive agency providing comprehensive solutions and services for healthcare agencies and brands.

“Demand for digital and social media solutions has expanded rapidly among our clients as physicians, patients and payers have grown more technically savvy,” said Paul Meister, CEO of inVentiv Health. “Kazaam Interactive helps us to meet this growing demand with digitally-based programs that have been proven to deliver value. The combination of Kazaam’s cutting-edge technology with inVentiv Commercial’s broad expertise in healthcare PR and communication will result in fully-integrated and powerful solutions for our clients.”

The acquisition of Kazaam Interactive will be fully funded with equity from funds affiliated with Thomas H. Lee Partners, L.P. (“THL”) and other existing stockholders. THL, along with Liberty Lane IH LLC and other co-investors, acquired inVentiv in August 2010.

“inVentiv is well-positioned to capture additional market share through its range of products and services,” said Todd Abbrecht, Managing Director of THL. “THL’s equity funding for the Kazaam acquisition reinforces our commitment to working with the senior leadership team at inVentiv to strengthen its position as a best-in-class global pharmaceutical services company. We will continue to work closely with the Company to develop additional opportunities to maximize the global market opportunity for their expanded service offering."

Kazaam Interactive will be part of inVentiv Health Communications, the public relations and advertising group within inVentiv’s Commercial segment. The acquisition will broaden inVentiv’s ability to provide clients with comprehensive digital solutions from strategy through execution and will augment its digital expertise across multiple businesses.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv’s client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. For more information, visit http://www.inventivhealth.com.

About Thomas H. Lee Partners, L.P.
Thomas H. Lee Partners, L.P. ("THL") is one of the world's oldest and most experienced private equity firms. The firm invests in growth-oriented global businesses, headquartered primarily in North America, across three sectors: Business & Financial Services, Consumer & Healthcare and Media & Information Services. THL's teams partner with portfolio company management to identify and implement business process improvements that accelerate sustainable revenue and profit growth. THL strives to build great companies of lasting value and generate superior investment returns. Since its founding in 1974, THL has raised more than $22 billion of equity capital, acquired more than 100 portfolio companies and has completed over 200 add-on acquisitions, representing a combined value of more than $150 billion.

About Kazaam Interactive
Kazaam is a full-service digital marketing agency offering premier digital strategy and solutions to brands and organizations. The company has worked with over sixty of the world’s largest brands and brings a real-world understanding for utilizing the online channels to strategically and tactically connect brands, organizations and customers. Kazaam’s strong customer focus, passion for excellence, and innovative thinking has fueled the company’s growth in revenue and client engagements throughout each of its first four years in business.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced and future acquisitions; whether funds affiliated with THL and/or other existing stockholders will agree to provide additional funding to support future acquisitions or other growth initiatives; the impact of any additional leverage we may incur in connection with the financing of acquisitions, on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; our ability to convert backlog into revenue; the potential liability associated with bringing new drugs to market, including potential liability from injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memorandums provided in connection with the issuance of our senior secured notes for further discussion of these risks and other factors.

Healthcare Businesswomen’s Association Names Five inVentiv Health Associates 2012 “Rising Stars”

Burlington, Mass. – May 1, 2012 – inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, announced today that five of its associates will be honored as 2012 “Rising Stars” by the Healthcare Businesswomen’s Association (HBA). The honorees include Marianne Eisenmann, Nida Khan, Lauren Miller, Krista Pinto and Erin Rossi.

Each year, the HBA recognizes women in the healthcare industry who exhibit leadership skills, who are dedicated to the healthcare industry, and who contribute significantly to their organizations. To qualify as Rising Stars, nominees must also promote growth opportunities for others and serve as role models within their respective companies.

The combined experience of the five inVentiv Rising Stars spans several decades and a variety of specialties across the healthcare field. On May 3, 2012, the 2012 honorees will be recognized at the 23rd annual HBA Woman of the Year Award luncheon in New York City.

“On behalf of inVentiv Health, I would like to congratulate Marianne, Nida, Lauren, Krista and Erin on this recognition,” said Paul Meister, CEO of inVentiv Health. “In an industry characterized by increasing complexity and a constant demand for innovation, having strong leaders with a passion for healthcare and a commitment to client service is critical. Our Rising Stars exemplify this standard and serve as role models for our entire organization.”

In addition to inVentiv, the five Rising Stars represent four of the company’s best-in-class businesses—Campbell Alliance, Chandler Chicco Companies, GSW Worldwide and Palio.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv’s client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

inVentiv Health Completes Acquisition of Kforce Clinical Research

Burlington, Mass. – April 3, 2012 – inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, announced that it has completed the acquisition of Kforce Clinical Research, Inc. (“KCR”), a provider of functional outsourcing solutions to pharmaceutical, biotech and medical device companies, from Kforce Inc. for $50 million in cash. The transaction closed on March 30, 2012.

KCR will be combined with inVentiv’s existing functional service provider (FSP) and staffing businesses within PharmaNet/i3, inVentiv Health’ s Clinical segment. The business will deliver a full spectrum of clinical staffing and resourcing solutions, ranging from recruitment of clinical development staff in all therapeutic areas to strategic FSP partnerships across multiple clinical trials and global geographies.

“Our investments in leading providers of clinical research services over the past year reflect our strong belief that clinical outsourcing will continue to grow as clients look to drive cost savings and flexibility while ensuring the highest quality in their organizations,” said Paul Meister, CEO of inVentiv Health. “Further enhancing our Clinical segment capabilities with KCR, and marrying these comprehensive clinical services with our commercial and consulting expertise, will allow inVentiv Health to deliver innovative solutions that add value, speed and quality to the drug development process.”

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv’s client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigtion Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced and future acquisitions and our ability to achieve the anticipated KCR revenue described in this release; the impact of any additional leverage we may incur in connection with the financing of acquisitions, on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; the potential liability associated with bringing new drugs to market, including potential liability from injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memorandums provided in connection with the issuance of our senior secured notes for further discussion of these risks and other factors.

inVentiv Health To Acquire Kforce Clinical Research

Acquisition Will Expand inVentiv’s Position as a Leader in the CRO Industry

inVentiv Also Announces Plans to Complete Acquisition of SDI Health Promotional and Medical Audit Businesses from IMS Health

Burlington, Mass. ‒ March 19, 2012 – inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that it has signed a definitive agreement to acquire Kforce Clinical Research, Inc. (“KCR”), a provider of functional outsourcing solutions to pharmaceutical, biotech and medical device companies, from Kforce Inc. for $50 million in cash.

KCR will be combined with inVentiv’s existing functional service provider (FSP) and staffing businesses within the Clinical segment, expanding inVentiv’s position as a leader in functional outsourcing and CRO services. With more than 30 years of experience and a broad portfolio of partners worldwide, the combined organization will leverage inVentiv Health’s global reach, enabling the company to meet clients’ strategic resourcing needs in more than 40 countries around the world.

“With its strong clinical monitoring expertise, a customer-focused approach and an impressive portfolio of clients, Kforce Clinical Research is an attractive complement to inVentiv’s existing services. This acquisition expands our capability across the continuum of FSP, staffing and CRO services, further enhancing our ability to deliver flexible, cost-effective solutions for our clients,” said Paul Meister, CEO of inVentiv Health.

KCR’s range of clinical services include: site management and monitoring, clinical project and program management, clinical programming and data management, biostatistical analysis and reporting, pharmacovigilance, medical writing, regulatory affairs, and quality assurance and training. inVentiv anticipates adjusted annualized revenue of approximately $70 million, which reflects the previously disclosed contract loss by KCR and anticipated wins and contract expansion.

The transaction is expected to close at the end of March 2012.

inVentiv Health also announced today that the Federal Trade Commission has approved its acquisition of SDI Health promotional and medical audit businesses from IMS Health. inVentiv expects to close the transaction this week. The syndicated offerings of the acquired businesses will be combined with the market research capabilities of Campbell Alliance, an inVentiv Health company and the leading management consulting firm specializing in the pharmaceutical and biotech industry.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv’s client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

inVentiv Health Launches MySTRO, a Multichannel Marketing Company

MySTRO Introduces Reptivate™ Virtual Detailing Solution to Accelerate the Delivery of Consistent Brand Messages to Healthcare Practitioners

PROMOTECH and PRS Franklin Rebrand as MySTRO to Reflect Expanded Expertise and Integrated Capabilities

Burlington, Mass. March 8, 2012 – inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that it has launched MySTRO, a multichannel marketing and sales solutions company. Reflecting inVentiv’s expanded expertise and integrated capabilities, MySTRO provides healthcare companies with seamless sales force support, telephone and remote personal selling, print and direct mail, sample accountability and compliance services.

MySTRO brings together two legacy inVentiv businesses: PROMOTECH and PRS Franklin. The company’s new branding conveys the strength of MySTRO’s integrated offerings, as well as its ability to orchestrate success by delivering innovative, comprehensive and customized marketing and sales support services to clients in the pharmaceutical, healthcare and life sciences industries. Additionally, by designing solutions based on clients’ individual needs, MySTRO builds relationships with customers that allow them to remain in command of strategic business decisions.

“In an economic landscape which is demanding improved efficiency and enhanced quality, healthcare companies are under enormous pressure to reduce costs and maximize their spend related to sales and marketing activities,” said Chuck Shea, Executive Vice President of inVentiv Health Commercial. “MySTRO’s multichannel marketing solutions provide clients with an effective and highly efficient way to reach healthcare practitioners, support and augment field forces, fulfill orders and provide best-in-class customer service to patients. Our solutions help customers drive efficiencies, remain compliant and reduce costs. As part of inVentiv Health, MySTRO offers healthcare companies the convenience of working with a single partner that can manage all of their needs in a coordinated and collaborative way.”

As part of its launch, MySTRO is also introducing Reptivate™, a virtual detailing product that uses cutting-edge digital technology to accelerate and enhance direct-to-healthcare provider interactions and increase prescription growth, while keeping cost levels low for clients. Reptivate’s integration with MySTRO’s call center CRM and sample inventory management systems presents customers with turnkey solutions for virtual detailing that include promotional offer solicitation, fulfillment and sample accountability. In addition, Reptivate – a Web-based tool – consistently delivers a brand’s educational messages by allowing doctors to receive the same medical information from MySTRO’s call center staff in a virtual environment as they would from sales representatives who meet with physicians in person.

“The customer experience, as a result, is better and more impactful because doctors can view rich, highly animated creative assets – using most electronic devices – without limitations or connection speed issues,” Shea added. “With Reptivate, MySTRO can offer healthcare companies a complete suite of customizable services that accelerate performance.”

To learn more about MySTRO or Reptivate, please contact Kolby Barbera at kbarbera@inventivhealth.com or 978-270-8999. Additional information is also available at http://mystromultichannel.com/index.html.

About MySTRO
MySTRO, an inVentiv Health company, is a leading provider of multi-channel marketing and sales force support solutions to clients in the pharmaceutical, healthcare and life-science industries. With offices in Louisville, Colorado and Totowa and Somerset, New Jersey, and more than 50 years of experience, MySTRO brings together two legacy inVentiv businesses: PROMOTECH and PRS Franklin. It provides healthcare clients with seamless sales force support, telephone and remote personal selling, print and direct mail, warehousing, fulfillment and data management services. The company also offers complete outsourced sample accountability, regulatory and PDMA compliance services to mitigate risks and ensure the appropriate promotion and distribution of prescription and controlled-substance product samples. For more information, visit http://mystromultichannel.com/index.html.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv’s client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

inVentiv Health Communications/Europe Establishes Headquarters

New Business Hub Officially Opens in London to Support the “Super Agency’s” Continued Growth

Executives Named to Lead Digital and Social Media, Advertising and Creative Services

London – February 28, 2012 – inVentiv Health Communications/Europe (iHCE), an inVentiv Health company and leader in global healthcare communications, today announced the official opening of its new headquarters in London to serve as a hub for all European offices and support the rapid growth of the company’s consolidated communications business.

iHCE, dedicated to delivering exceptional multi-channel, multinational marketing, will provide governance and operational support to enhance customer service across all communications offices and foster closer collaboration with inVentiv Health’s other commercial services including sales and patient outcomes.

inVentiv Health is a global provider of clinical, commercial and consulting services to the healthcare industry and last August announced the launch of iHCE. Since then, iHCE has focused on building a “Super Agency” governed by a single management philosophy that facilitates true collaboration between inVentiv’s best-in-class advertising, public relations, public policy, market access, medical education, marketing, branding and digital services.

Done as One

iHCE’s new operational hub enables this “Done as One” management philosophy that removes barriers between communications disciplines to create teams that view problems from multiple perspectives and then draw upon the needed expertise to deliver programmes that quickly achieve their goals.

“From deep collaboration emerge solutions that are unique in the healthcare industry,” said Bob Chandler, Senior Vice President of Marketing and Communications of inVentiv Health and Head of iHCE. “Our company structure allows us to draw upon a wealth of talent and deep insight across many disciplines, while our new European Headquarters helps us better serve our clients and facilitate growth throughout Europe. This is a very exciting time.”

iHCE’s leadership team also announced the appointment of Nick Bartlett, Damon Caiazza and Peter Comber to senior management roles. Bartlett will lead iHCE’s digital and social media business, Caiazza will head advertising, and Comber will oversee the company’s creative services.

Bartlett joins iHCE from Publicis Life Brands Resolute, where he held the position of Digital Strategy Director. iHCE promoted both Caiazza and Comber, who fulfilled similar roles at GSW Europe, an inVentiv Health company. All three will work closely within specific markets and with inVentiv business units to support ambitious goals for local and regional growth through the delivery of best-in-class services.

Fiona Hall, Senior Managing Director of iHCE, said, “We are committed to providing clients with a multidisciplinary approach that taps the expertise of all healthcare marketing disciplines, and today’s appointments reinforce this commitment. As part of our senior management team, Nick, Damon and Peter will support our go-to-market strategy rooted in client demand for effective, actionable multidisciplinary services that reach target audiences with greater speed and relevance.”

About inVentiv Health Communications/Europe
inVentiv Health Communications/Europe (iHCE) is a full-spectrum, healthcare specialist “Super Agency” dedicated to delivering exceptional multi-channel and multinational marketing programmes. iHCE provides relevant, targeted and flexible marketing solutions for the pharmaceutical industry and organisations with a healthcare focus, enabling clients to excel in a rapidly changing environment. The company’s unified offer brings together inVentiv Health’s advertising, public relations, public policy, market access, medical education, marketing, digital and branding services. The company is based in Switzerland with operational headquarters in London.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv’s client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

inVentiv Health Hires Industry Veteran Tom Sebok to Lead Companies within Advertising Group

Burlington, Mass. – February 23, 2012 - inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that Tom Sebok will be leading the company’s advertising segment as the new President of inVentiv Health Communications. Sebok brings decades of communications expertise to inVentiv clients seeking to reach and motivate healthcare professionals and consumers.

Sebok’s hiring coincides with inVentiv’s realignment of communications services into functional groups, with one concentrating on advertising and paid media and the other focused on public relations and medical education. In his new role, Sebok will oversee GSW Worldwide, Ignite Health, The Navicor Group, Addison Whitney, Palio, Patient Marketing Group and inServ. He will be based in New York and report to Paul Meister, CEO of inVentiv Health, Inc.

“No other organization has such a breadth of healthcare experience and few can match the depth of inVentiv Health Communications talent,” Meister said. “Tom’s experience deepens our ability to help advertising clients reach and motivate consumers and professionals in the healthcare field. We are delighted that he is joining us.”

The public relations group within inVentiv will continue to be led by Bob Chandler, President and CEO of Chandler Chicco Companies, who also will oversee the inVentiv Medical Education Group (iMEG) and report to Meister. “We see many opportunities for collaboration between PR and medical education on behalf of our clients, particularly as we expand this business globally,” Meister said. “Working in close collaboration, Tom and Bob will lead teams offering the best services to a market demanding multi-specialty solutions.”

Sebok previously served as President and CEO of Young & Rubicam's flagship New York agency, providing integrated marketing communications solutions for clients such as the Arthritis Foundation, Bayer Women's Health, Campbell's, Colgate-Palmolive, Chevron, Dell, Goldman Sachs, Hilton, J&J, Land Rover, LG, Mattel, Microsoft, Pfizer, USOC, Virgin Atlantic and Xerox. Prior to Y&R, Tom spent the bulk of his career at BBDO where he led that agency's global service of clients such as Bayer Consumer Care, Campbell's, FedEx, Frito-Lay, Lowe's, Motorola, PepsiCo and Pizza Hut. As Managing Director of BBDO New York, Tom was a key leader in BBDO's reinvention as an agency that excels in both traditional and new media. Earlier in his career he worked at Grey Advertising on the Beecham Products consumer business (now SKB) and Boehringer Ingelheim.

About inVentiv Health Communications
inVentiv Health Communications (iHC) is a full-spectrum, healthcare specialist agency dedicated to delivering exceptional multi-channel and multinational marketing programs. iHC provides relevant, flexible and cost-effective marketing solutions for the pharmaceutical industry and organizations with a healthcare focus, enabling clients to succeed in a rapidly changing environment.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv’s client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

inVentiv Health to Acquire SDI Promotional and Medical Audit Businesses from IMS Health

Burlington, Mass. – January 17, 2012 - inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that it has entered into a definitive agreement to acquire certain promotional and medical audit businesses of SDI Health, which IMS Health has committed to divest in connection with obtaining regulatory approval of its acquisition of SDI. Financial terms of the transaction were not disclosed.

The business will be incorporated into the offerings of Campbell Alliance, an inVentiv Health company and the leading management consulting firm specializing in the pharmaceutical and biotech industry. Through the acquisition, Campbell Alliance adds a robust range of promotional and medical audits based on proprietary research that leading healthcare companies use to better understand their markets and make more highly informed business decisions.

“This is an important step in boosting inVentiv’s capabilities in market research and analytics,” said Paul Meister, Chief Executive Officer of inVentiv Health. “In combination with our leading consulting services, these additional capabilities allow us to provide a more comprehensive offering that augments our clients’ business decision-making.”

Campbell Alliance’s market research and analytics group will combine the acquired business with its current custom quantitative research, qualitative market research, key opinion leader identification and mapping, access to a range of longitudinal de-identified patient and prescription data, and integrated analytics services. In addition, the group currently offers complementary audits, including its Metropolitan Promotional Audit (MPA) and VisionCare contact lens audit.

Nader Naeymi-Rad, CEO of Campbell Alliance, added, “We’re seeing a growing demand for proprietary research services from our Campbell Alliance clients and believe that our enhanced market research capabilities, particularly the ones acquired on the syndicated side, will allow us to establish a leadership position in that market.”

The transaction is subject to customary closing conditions and approval by the Federal Trade Commission following a public comment period, and is expected to close in February 2012.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv’s client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

About Campbell Alliance
Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance. Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm's clients include all of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Commercial Effectiveness, Pricing and Market Access, and Medical Affairs. From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.

About IMS Health
IMS Health is the leading provider of information, services and technology for the healthcare industry around the world. The company draws on its global technology infrastructure and unique combination of in-depth, sophisticated analytics, on-shore and off-shore commercial services, and consulting platforms to help clients better understand the performance and value of medicines. With a presence in 100+ countries and more than 55 years of industry experience, IMS serves leading decision makers in healthcare, including pharmaceutical manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community. Additional information is available at http://www.imshealth.com.

inVentiv Health Takes Home Eight MM&M Awards

Burlington, Mass. - October 13, 2011 - inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that inVentiv Health companies won a total of eight awards at the 2011 Medical Marketing & Media (MM&M) Awards, held in New York City on October 11. Biosector 2, Ignite Health and Patient Marketing Group each took home at least one Gold award, and Chandler Chicco Agency and Chamberlain Healthcare Public Relations took home Silver awards. Blue Diesel was recognized with both a Gold and Silver award.

The MM&M Awards recognize exceptional creativity and marketing effectiveness in the healthcare sector. Winners are selected by an independent panel of experts drawn from the fields of marketing, media and advertising.

  • Biosector 2, a leading global healthcare public relations agency, was recognized with two Gold awards, including Best Use of Public Relations and Best Use of Social Media, for its work with Boehringer Ingelheim on Drive4COPD.
  • Blue Diesel, a full-service, integrated advertising agency, won a Gold award in the category of Best Agency Self-Promotion for its promotional campaign featuring the fictional character Douglas Fur. Blue Diesel also took home the Silver award for Best Branded Website for Merck's MerckVaccines.com.
  • Chandler Chicco Agency, the world's largest pure-play healthcare public relations firm, was honored with the Silver award for Best Use of Public Relations for its work with Sanofi on AF Stat: A Call to Action for Atrial Fibrillation.
  • Chamberlain Healthcare Public Relations, a leading global healthcare public relations agency, was recognized in the Best Use of Social Media category with a Silver award for its work with Boehringer Ingelheim on HealthSeeker: Simple Steps, Healthier Together.
  • Ignite Health, a leading marketing agency that delivers a full range of promotional solutions in the health and wellness market, received the Gold award for Best Disease/Education Website for its work with Vertex Pharmaceuticals on BetterToKnowC.
  • Patient Marketing Group, specializing in the development of innovative patient relationship marketing programs, was honored with the Gold award for Best Online Patient Relationship/Support Program for work with Merck on MerckEngage&emdash;MerckEngage Health Partnership Program.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv's client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, www.inventivhealth.com.

inVentiv Health Launches EMBARX™, an Integrated Solution for Market Access Challenges

Burlington, Mass. ‒ April 18, 2012 – inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that it has launched EMBARX™, a customizable, patient-centric offering to meet the market access challenges of specialty biotech and pharmaceutical products. EMBARX draws upon leading industry experts from inVentiv’s Clinical, Commercial and Consulting segments and uses state-of-the-art technology to create comprehensive solutions that improve patient access, increase commercial value, and drive adherence and loyalty to clients’ products.

EMBARX includes services such as strategic consulting, reimbursement support, clinical nursing teams, adherence programs, REMS, payer communications, and field teams support. EMBARX leaders bring a thorough understanding of specialty diseases, product cycles, care settings, product markets and drug class characteristics. Each EMBARX solution is completely customized with the patient, provider, and payer in mind. Because the services are delivered through inVentiv Health, clients experience the convenience and efficiency of working with one provider to manage fully integrated, multi-service programs.

“While a growing number of innovative specialty products are being introduced to the market, it is also becoming increasingly difficult for patients to access those therapies due to regulatory, cost and educational barriers,” said Mark Dmytruk, President of inVentiv Health Patient Outcomes. “EMBARX leverages inVentiv’s talent and experience to provide powerful solutions to these market access challenges. Through our integrated teams, we not only support the business goals of our clients, we also help drive improved patient outcomes.”

To learn more about EMBARX, please contact Anthony Piagentini, Executive Director, Business Development, at anthony.piagentini@inventivhealth.com or 732-584-5288. Additional information is also available at http://www.inventivhealth.com/embarx.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv’s client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.